Title: ANTI-NET COMPOUNDS FOR TREATING AND PREVENTING FIBROSIS AND FOR FACILITATING WOUND HEALING

Abstract: Embodiments of the technology described herein are based, in part, upon the discovery that NETosis, the formation of neutrrophil extracellular traps (NETs) is increased in wounds, in organ fibrosis and in subjects with diabetes. Accordingly, methods for treating wounds, fibrosis and NET associated complications in diabetes are provided. The methods comprise administering a therapeutically effective amount of at least one anti-NET compound to a subject in need of treatment, e.g. a PAD 4 inhibitor, a DNase, a histone-degrading enzyme; an inhibitor of chromatin decondensation; an antibody against a component of a NET; an inhibitor of NET release, a protease inhibitor, or an elastase inhibitor.

FIG. 3D
ANTI-NET COMPOUNDS FOR TREATING AND PREVENTING FIBROSIS AND FOR FACILITATING WOUND HEALING

Cross Reference to Related Applications

This Application claims the benefit under 35 U.S.C. 119(e) of U.S. Provisional Application Serial Number 62/105,342 filed on January 20, 2015, the contents of which are herein incorporated by reference in their entirety.

Federal Funding

This invention was made with federal funding under Grant No: RO1HL102101 awarded by the National Institutes of Health. The U.S. government has certain rights in the invention.

Technical Field

The technology described herein relates to methods of treating and preventing organ fibrosis due to interstitial collagen deposition and to methods for treatment of wounds, as well as methods for treatment of NET associated complications in diabetes.

Background

Fibrosis is the formation of excess extracellular matrix components such as collagen in an organ or tissue. In this process functional parenchymal organ tissue is replaced by fibrotic tissue, which can severely diminish organ function. Fibrosis is typically a result of chronic inflammation induced by a variety of stimuli including persistent infections, autoimmune reactions, allergic responses, chemical insults, radiation and tissue injuries.

In spite of the well-known connection between fibrosis and inflammation, the role of neutrophilic granulocytes in fibrosis in general and in age-related organ fibrosis in particular has remained elusive. Neutrophils constitute the "first line of defense" in inflammatory processes, migrating to the site of injury within minutes after insult. Neutrophils possess a large repertoire of defense mechanisms to combat pathogens, including phagocytosis and the release of bactericidal proteins such as myeloperoxidase (Mayadas et al. (2014) Annu Rev Pathol 9:181-218). In response to activating signals, neutrophils in vitro and in vivo efficiently form NADPH oxidase complexes which lead to the production of cell permeable reactive oxygen species (ROS) (Clark RA (1999) J Infect Dis 179 Suppl 2:S309-317).
Several years ago, a new defense mechanism of neutrophils, a process termed NETosis, was discovered. Here, neutrophils release their chromatin as neutrophil extracellular traps (NETs) covered with antimicrobial peptides to trap and kill pathogens (Brinkmann V, et al. (2004) Science 303(5663): 1532-1535). This mechanism critically depends on the enzyme peptidylarginine deiminase 4 (PAD4), which citrullinates specific arginine residues on histone tails, resulting in the decondensation of chromatin which occurs prior to the release of NETs (Wang Y, et al. (2009) J Cell Biol 184(2):205-213).

Unfortunately, NETosis also occurs under non-infectious conditions such as hypoxia (De Meyer SF et al. (2012) Arterioscl Thromb Vase Biol 32(8): 1884-1891) or sterile inflammation as in autoimmune diseases (Kolaczkowska E & Kubes P (2013) Nat Rev Immunol 13(3): 159-175). NETs are injurious to the endothelium and underlying tissue as histones are strongly cytotoxic and pro-inflammatory, promoting neutrophil migration and, at high concentrations, even host death (Xu J, et al. (2009) Extracellular Histones Are Major Mediators of Death in Sepsis. Nat Med 15(1): 1318-1321).


Organ fibrosis is a pathological condition associated with chronic inflammatory diseases and aging. In fibrosis, excessive deposition of extracellular matrix (ECM) severely impairs tissue architecture and function, eventually resulting in organ failure. It has been determined that the process is mediated primarily by the induction of myofibroblasts, which produce large amounts of collagen I, the main component of the ECM (Satoshi Uehal et al., (2012) Front. Immunol., 3:(71):1-6). Accordingly, the origin, developmental pathways, and mechanisms of myofibroblast regulation have attracted attention as potential therapeutic targets, but other pathways may be involved. Gaining an
understanding of the mechanisms behind organ fibrosis can provide new targets for the treatment for the devastating affects it has on organ function.

**Summary**

Herein, we evaluated whether NETosis, which is regulated by ROS prominent in aging (Tabas I & Glass CK (2013) *Science* 339(61 16): 166-172; and Akong-Moore K, et al. prominent aging (2012) *PloS One* 7(8):e42984), is linked to fibrosis. Embodiments of the invention are based in part on the discovery that peptidylarginine deiminase 4 (PAD4), a key enzyme needed for the formation of NETS, promotes age related organ fibrosis. In particular, we investigated the role of NETs in age-related organ fibrosis and heart dysfunction. We show that neutrophil counts increase in old mice and that these neutrophils are more susceptible to form NETs than neutrophils from young mice. We studied organs of young and old wild-type (WT) and peptidylarginine deiminase 4 (PAD4)-deficient mice that are defective in NETosis. Indeed, PAD4−/− mice were protected from age-related decline in systolic and diastolic heart function as determined by echocardiography.

We evaluated left ventricular interstitial fibrosis in both genotypes and found an age-related increase of interstitial collagen only in the hearts of WT mice. The level of fibrosis correlated with the degree of systolic heart dysfunction. A partial protection from fibrosis was found in the lungs of old PAD4−/− mice compared to old WT mice. Accordingly, there is a general role for PAD4 NETs in the etiology of organ fibrosis, thus PAD4 NETs are a novel target for treatment of organ fibrosis.

In one aspect of the invention, provided herein are methods for treating or preventing organ fibrosis. The method comprises administering to a subject in need of treatment, a therapeutically effective amount of at least one anti-NET compound.

In certain embodiments, the subject is diagnosed as having age-related organ fibrosis, or with an organ fibrosis selected from the group consisting of: heart fibrosis, lung fibrosis, liver fibrosis, kidney fibrosis, skin fibrosis, soft tissue fibrosis, and intestine fibrosis.

In certain embodiments, the anti-NET compound is selected from the group consisting of: DNase; a histone-degrading enzyme; an inhibitor of chromatin decondensation; an antibody against a component of a NET; a protease inhibitor, an elastase inhibitor; and a PAD4 inhibitor. In certain embodiments, the PAD4 inhibitor is selected from the group consisting of: Cl-amidine and F-amidine. In certain embodiments, the inhibitors are selective PAD4 inhibitors that are reversible, e.g. including but not limited to GSK484 and GSK199 (Nat. Chem. Biology, in Press).
In certain embodiments, the PAD4 inhibitor is a tetrazole analog, e.g. as described in Subramanian et al., Design, synthesis and biological evaluation of tetrazole analogs of Cl-amidine as protein arginine deiminase inhibitors J. Med. Chem., DOI: 10.1021/jm501636x. Publication Date (Web): January 5, 2015.

In one embodiment the tetrazole analog is biphenyl tetrazole tert-butyl Cl-amidine (BTT-Cl-amidine) that exhibits enhanced cell killing in a PAD4 expressing cells also blocks the formation of neutrophil extracellular traps (Subramanian et al., Supra).

In certain embodiments, the PAD4 inhibitor is a peptidomimetic compound, e.g. including but not limited to 1,2,3-triazole peptidomimetic based derivatives incorporating beta-phenylalanine and guanidine scaffolds, e.g. as described in Trabocchi et al. Peptidomimetics as protein arginine deiminase 4 (PAD4) inhibitors, J. Enzyme Inhib. Med. Chem., early online 1-6 (2014): DOI: 10.3 109/147563662014947976. See also Figure 13 that illustrates chemistry for 16 peptidomimetic PAD4 inhibitors as described in Trabocchi et al. Supra, e.g. 1,2,3-triazole peptidomimetic based derivatives.

In certain embodiments, the anti-NET compound is an inhibitor of NET release from cells, e.g. Cl-amidine blocks NET release from NZM neutrophils in vitro, other inhibitors of NET release are known to those of skill in the art.


In certain embodiments, the PAD4 inhibitor is YW3-56, as described in Wang et al., (2012) J. Biol. Chem 287(3 1):25941-53.

In certain embodiments, the therapeutically effective amount of anti-NET compound is administered prophylactically to the subject, e.g. repeated administration for prevention of fibrosis. In certain embodiments, the subject's age is selected from the group consisting of: over 40 years of age, over 30 years of age, over 50 years of age, over 60 years of age, and over 70 years of age, and e.g. prophylactic administration prevents the progression or onset of fibrosis in aging adults.

In certain embodiments, the subject is diagnosed with a disease selected from the group consisting of: heart disease, lung disease, kidney disease, liver disease, and diabetes, and e.g. prophylactic administration thereby prevents the progression or onset of fibrosis in patients having the disease. In certain embodiments, the lung disease is not cystic.
fibrosis. In certain embodiments, the anti-NET compound is not a PAD4 inhibitor and is selected from the group consisting of a DNase; a histone-degrading enzyme; an inhibitor of chromatin decondensation; an antibody against a component of a NET; a protease inhibitor, and an elastase inhibitor.

In one embodiment, the anti-NET compound is administered locally to one or more target sites in the organ with fibrosis or susceptible to fibrosis, e.g. by injection, or by topical application.

In certain embodiments, the subject with fibrosis does not have cystic fibrosis.

Herein we have also determined that neutrophils isolated from type 1 and type 2 diabetic patients and mice were primed to NETosis. Expression of peptidylarginine deiminase 4 (PAD4), an enzyme important in chromatin decondensation, was 4-fold elevated in neutrophils of diabetics. When subjected to excisional skin wounds, wild-type (WT) mice produced large quantities of NETs at the wound site, but this did not happen in \( \text{PAD4}^{-} \) mice. Higher levels of NET biomarkers were found in the wounds of diabetic mice, accompanied by a significant delay in healing. Impressively, \( \text{PAD4}^{-} \) mice healed faster than WT mice, and their wound healing was not compromised by diabetes. DNase 1, which disrupts NETs, accelerated wound healing in WT mice. We conclude that NETs impair wound healing, especially in diabetes where neutrophils are more susceptible to NETosis. Thus, inhibiting NETosis or cleaving NETs is a therapeutic strategy to improve wound healing and reduce NET-driven chronic inflammation in diabetes.

Accordingly, in another aspect of the invention, methods for facilitating wound healing are provided. The methods comprise administering a therapeutically effective amount of at least one anti-NET compound. In certain embodiments, the anti-NET compound used to facilitate wound healing is not a DNase.

In certain embodiments the subject to be treated with an anti-NET compound in order to facilitate wound healing is diagnosed as having diabetes.

In yet another aspect of the invention, methods for treating NET associated complications in diabetes are provided. The methods comprise administering a therapeutically effective amount of at least one anti-NET compound. In certain embodiments, the inflammation associated with diabetes is decreased by at least 10%, at least 20%, at least 30%, or at least 50%. In certain embodiments, wound healing facilitated by at least 10%, at least 20%, at least 30%, or at least 50%.
In certain embodiments, in each of the above aspects, the anti-NET compound is selected from the group consisting of: DNase; a histone-degrading enzyme; an inhibitor of chromatin decondensation; an antibody against a component of a NET; a protease inhibitor, an elastase inhibitor; and a PAD4 inhibitor.

In certain embodiments, in each of the above aspects, the PAD4 inhibitor is selected from the group consisting of: Cl-amidine and F-amidine. In certain embodiments, the inhibitors are selective PAD4 inhibitors that are reversible, e.g. including but not limited to GSK484 and GSK199 (Nat. Chem. Biology, in Press).

In certain embodiments, in each of the above aspects, the PAD4 inhibitor is a peptidomimetic compound, e.g. including but not limited to 1,2,3-triazole peptidomimetic based derivatives incorporating beta-phenylalanine and guanidine scaffolds, e.g. as described in Trabocchi et al. Peptidomimetics as protein arginine deiminase 4 (PAD4) inhibitors, J. Enzyme Inhib. Med. Chem., early online 1-6 (2014): DOI: 10.3 109/147563662014947976. See also Figure 13 that illustrates chemistry for 16 peptidomimetic PAD4 inhibitors as described in Trabocchi et al. Supra, e.g. 1,2,3-triazole peptidomimetic based derivatives.

In certain embodiments, in each of the above aspects, the PAD4 inhibitor is a tetrazole analog, e.g. as described in Subramanian et al., Design, synthesis and biological evaluation of tetrazole analogs of Cl-amidine as protein arginine deiminase inhibitors J. Med. Chem., DOI: 10.1021/jm501636x Publication Date (Web): January 5, 2015.

In one embodiment, in each of the above aspects, the tetrazole analog is biphenyl tetrazole tert-butyl Cl-amidine (BTT-Cl-amidine) that exhibits enhanced cell killing in a PAD4 expressing cells also blocks the formation of neutrophil extracellular traps (Subramanian et al., Supra).

In certain embodiments, in each of the above aspects, the PAD4 inhibitor is YW3-56, as described in Wang et al., (2012) J. Biol. Chem. 287(3 1):25941-53.

In certain embodiments, in each of the above aspects, the PAD4 inhibitor is a peptidomimetic compound, e.g. including but not limited to 1,2,3-triazole peptidomimetic based derivatives incorporating beta-phenylalanine and guanidine scaffolds, e.g. as described in Trabocchi et al. Peptidomimetics as protein arginine deiminase 4 (PAD4) inhibitors, J. Enzyme Inhib. Med. Chem., early online 1-6 (2014): DOI: 10.3 109/147563662014947976. See also Figure 13 that illustrates chemistry for 16 peptidomimetic PAD4 inhibitors as described in Trabocchi et al. Supra, e.g. 1,2,3-triazole peptidomimetic based derivatives.
[0034] In certain embodiments, in each of the above aspects, the anti-NET compound is an inhibitor of NET release from cells, e.g. Cl-amidine blocks NET release from NZM neutrophils in vitro, other inhibitors of NET release are known to those of skill in the art.

[0035] In certain embodiments in each of the above aspects of the invention the anti-NET compound administered is not a DNase.

[0036] In certain embodiments in each of the above aspects of the invention the anti-NET compound is not an elastase inhibitor.

[0037] In certain embodiments in each of the above aspects of the invention more than one anti-NET compound is administered, e.g. a PAD4 inhibitor and a DNase, or aPAD4 inhibitor and an elastase inhibitor.

[0038] In certain embodiments in each of the above aspects of the invention the therapeutically effective amount of anti-NET compound is administered prophylactically.

[0039] In certain embodiments in each of the above aspects of the invention the therapeutically effective amount of anti-NET compound is given as a single dose of administration. In certain embodiments, the dose is given repeatedly.

[0040] In certain embodiments in each of the above aspects of the invention the composition comprising at least one anti-NET compound further comprises a pharmaceutically acceptable carrier. In further embodiments, the composition comprising at least one anti-NET compound further comprises another compound that is useful in treating or preventing the condition to be treated, e.g. wounds, fibrosis or NET driven inflammation and delayed wound healing in diabetes.

[0041] The details of various embodiments of the invention are set forth in the description below. Other features, objects, and advantages of the invention will be apparent from the description and the drawings, and from the claims. All references cited herein, in this specification, are herein incorporated by reference in their entirety for purposes of disclosure.

**Description of the Drawings**

[0042] Figures 1a to 1k indicate that diabetes or high glucose concentration in vitro primes human and murine neutrophils to undergo NETosis. Fig. 1a-Fig. 1c are graphs of HbAlc in Healthy subjects (black) and patients with diabetes mellitus (DM) (pink, type 1 DM; purple, type 2 DM) who were recruited and peripheral neutrophils were isolated from fresh whole blood. (Fig. 1a) All diabetic patients had HbAlc >6.5%. Fig. 1b is a graph indicating that more neutrophils isolated from diabetic patients formed NETs in vitro when
stimulated with ionomycin (4 µM), and Fig. 1c is a graph indicating these neutrophils expressed more PAD4 when compared to those from healthy subjects as reflected by Western blotting, inlay; diabetic first lane is type 1 diabetes, lane 2 and lane 3 type II diabetes. Fig. Id is a graph indicating that more high glucose (HG)-treated neutrophils from healthy subjects produced NETs with or without stimulation than those in normal glucose (NG) or mannitol (M). n = 5 per condition. Fig. le-Fig. li are graphs. Neutrophils were isolated from streptozotocin (STZ)-induced diabetic mice (Fig. le-Fig. lg) or db/db diabetic mice (Fig. lh-Fig. li) and stimulated with LPS from Klebsiella pneumoniae at indicated concentrations for 2.5 h. More neutrophils from STZ-induced diabetic mice or db/db mice were H3Cit\textsuperscript{high} (Fig. le, Fig. lh) and formed NETs (Fig. If, Fig. li), when compared to normoglycemic vehicle-treated control (Fig. le, Fig. If) or m+/db mice (Fig. lh, Fig. li). US, unstimulated, n = 12 for Vehicle, n = 10 for STZ; n = 6-7 for m+/db; n = 7-8 for db/db. Fig. lg are representative images of isolated neutrophils from vehicle- or STZ-treated mice, as labeled. Neutrophils were exposed to LPS (25 µg/mL) for 2.5 h. Arrows indicate NETs. Scale, 50 µm. Fig. lj and Fig. Ik are graphs illustrating more neutrophils isolated from normoglycemic wild-type mice and exposed to high glucose in vitro were (Fig. lj) H3Cit\textsuperscript{high} and (Fig. Ik) produced NETs. n = 10 per medium condition. *P<0.05, **P<0.01, ***P<0.001. (Fig. la-Fig. lc,Fig. lh, Fig. li) Mann-Whitney test; (Fig. Id, Fig. lj, Fig. Ik) repeated measures ANOVA followed by Bonferroni’s post test; (Fig. le, Fig. If) Student’s t test.

Figures 2a to 2b are Western blot and graphs illustrating that neutrophil H3Cit and extracellular chromatin are observed in the wounds of WT mice, indicating the formation of NETs. Fig. 2a is a Western blots showing the time course of H3Cit appearance after skin injury. Wounds were generated with biopsy punches at the dorsal skin of the mice. Scab and the surrounding 0.5 mm skin were collected at the time indicated. H3Cit was detectable starting day 1 post wounding and peaked from day 3 to 7. H3Cit was absent in the control unwounded skin (Ctrl). H3, histone H3. *P<0.05 versus Ctrl, Student's t test, n = 3-5. Immunofluorescence images of a 3-day wound bed immediately beneath scab showed cells were mostly positive for Ly6G and H3Cit (data not shown). Representative images of a 3-day wound using confocal microscopy showed H3Cit co-localized with extracellular DNA in the Ly6G (red)-positive area in the scab (data not shown). Fig. 2b are Western blots of 3-day wounds collected from mice with defective leukocyte recruitment (CD18\textsuperscript{-/-}, left) and mice depleted of neutrophils using an anti-Ly6G antibody (right, representative of n = 7).
H3Cit was markedly reduced in these wounds. IgG, IgG isotype control for the anti-Ly6G antibody.

Figures 3a to 3e indicate that PAD4 deficiency facilitates wound repair in normoglycemic mice. Fig. 3a is a representative Western blot of wounds from WT (+/+ ) and PAD4−/− (-/-) mice. H3Cit was absent in the wounds from PAD4−/− mice. Ly6G levels in wounds were similar in both genotypes (See also Fig 12a, Fig 12b). Fig. 3b is a panel of photographs of wounds of WT and PAD4−/− mice. Wounds of PAD4−/− healed faster and both healed without apparent signs of infection. Scale, 5 mm. Fig. 3c is a graph indicating changes in wound area compared to day 0. Wound area reduced faster in PAD4−/− mice starting day 1 post wounding. *P<0.05, **P<0.01, ***P<0.001 versus WT, Student's t test, n = 9-16. Fig. 3d is a graph indicating significantly more PAD4−/− mice had wounds completely closed by day 14. **P<0.01, two-tailed Fisher's exact test. Fig. 3e is a graph of re-epithelialization determined from H&E staining on 3-day wounds from WT and PAD4−/− mice (data not shown), re-epithelialization occurred faster in PAD4−/− mice. ***P<0.001, Student's t test, n = 6-9. Images of H&E staining and confocal microscopy of 3-day wounds from WT and PAD4−/− mice. H&E revealed the presence of extracellular DNA in the scab of WT mice, while neutrophils appeared intact (ring-shaped,) in PAD4−/− scabs (data not shown). Confocal immunofluorescence images (lower panels) showed intact neutrophil morphology and an absence of H3Cit in the scabs of PAD4−/− mice compared to the NETs in the scabs of WT mice (data not shown).

Figures 4a to 4i are graphs and Western blots indicating that PAD4 deficiency or DNase 1 treatment enhances wound healing in diabetic mice. WT and PAD4−/− mice were treated with vehicle or STZ. Wounding was performed 8 weeks after diabetic induction. All mice were provided with antibiotics (2.5% Sulfatrim) in the drinking water immediately after wounding. (Fig. 4a-Fig. 4h). Fig. 4a to Fig. 4c are graphs showing wound area reduction. Fig. 4d to Fig. 4f are graphs indicating percent mice with open wounds per time (Fig. 4a-Fig. 4h). Data from all groups were obtained simultaneously in multiple experiments but split into three graphs (Fig. 4a-Fig. 4c and Fig. 4d-Fig. 4f) to facilitate comparison. *P<0.05, **P<0.01, ***P<0.001 between groups on respective post-wounding day (Fig. 4a-Fig. 4c, Student's t test) or between curves (Fig. 4d-Fig. 4f, log-rank test), n = 6-9. (Fig. 4a) Wound healing was impaired in STZ-induced diabetic WT mice compared to normoglycemic mice (vehicle). (Fig. 4b) PAD4−/− mice had much faster wound repair than WT under diabetic conditions. (Fig. 4c) Diabetes did not impair wound repair in PAD4−/− mice. (Fig. 4d) STZ-
induced diabetic WT mice had delayed wound closure compared to normoglycemic mice (vehicle). (Fig. 4e) STZ-treated PAD4−/− mice achieved total wound closure earlier than STZ-treated WT mice. (Fig. 4f) Wound closure was not significantly different (NS) between normoglycemic (vehicle) and diabetic (STZ) PAD4−/− mice. Fig. 4g is a representative Western blot and summarized data (normalized to mean of vehicle) showing higher H3Cit levels in wounds from STZ-induced diabetic mice one day post wounding. (Fig. 4h, Fig. 4i) DNase 1 (dornase alfa) treatment facilitated wound area reduction (upper panels) and re-epithelialization (lower panels) in both (Fig. 4h) diabetic and (Fig. 4i) normoglycemic WT mice. (Fig. 4h) DNase 1 treatment did not provide additional benefits in wound healing in diabetic PAD4−/− mice. (Fig. 4h) *P<0.05, ***P<0.001 and NS non-significant using Kruskal-Wallis test followed by Dunn’s post test, †P<0.05, ††P<0.01 using Mann-Whitney test, n = 5-9. (Fig. 4i) *P<0.05, Student’s t-test, n = 9-10

Figures 5A to 5E are graphs showing that neutrophil and platelet count is increased in aging WT mice and so is neutrophil susceptibility to produce NETs: Fig. 5A is a graph of neutrophil counts in peripheral blood of young (8 weeks) vs. old (24 months) WT mice, n = 6-8. Fig. 5B is a graph of platelet counts in young (8 weeks) vs. old (24 months) WT mice, n = 6-8. Fig. 5C is a graph of quantification of the percent of H3Cit-positive neutrophils by thresholding analysis of immunostained cytospins of red blood cell-depleted blood cells, n = 6-8. Fig. 5D is a graph of quantification of Ly6G-positive neutrophils in the total leukocyte cytospin population, n = 6-8. In C and D, young mice were 6 - 8 weeks and old mice were 15 - 20 months old. Fig. 5E is a graph of the percentage of NET-forming peripheral blood neutrophils after incubation with vehicle (unstimulated, US), 4 µM ionomycin (iono), or 100 nM phorbol 12-myristate 13-acetate (PMA) for 3.5 h. Neutrophils from old (24 - 27 months) mice formed significantly more NETs under all conditions than neutrophils from young (2 - 5 months) mice, n = 5. *P < 0.05, **P < 0.01, ***P < 0.001.

Figures 6A to 6E are graphs and images indicating that PAD4−/− mice are protected from age-related decline in systolic and diastolic heart function compared to WT mice: Fig. 6A is 4 graphs of left ventricular ejection fraction (LVEF) as a measure of systolic function and cardiac dimensions (IVS;d, LVPW;d and LVID;d) of WT and PAD4−/− retired breeders (1217 months) were measured by transthoracic echocardiography. WT retired breeders showed a significantly reduced LVEF compared to PAD4−/− retired breeders. Cardiac dimensions were not significantly different between WT and PAD4−/− retired breeders, n = 7-11. Fig. 6B is 4 graphs, the same echocardiographic
measurements of LVEF and cardiac dimensions were repeated in a group of young (6 - 8 weeks) and old (14 - 18 months) WT and PAD4\(^{-/-}\) mice that had been kept on standard lab diet. Measurements showed similar results as in the retired breeders with a significant difference between the LVEF of old WT and old PAD4\(^{-/-}\) mice (left panel). LVEFs of old PAD4\(^{-/-}\) mice were comparable to young PAD4\(^{-/-}\) mice. Old WT and PAD4\(^{-/-}\) had similar cardiac dimensions. n = 4-7. **Fig. 6C** are representative ultrasound M-mode images of the left ventricle showed better contractility in the PAD4\(^{-/-}\) mice compared to the old WT mice. S, systole; D, diastole. **Fig. 6D** is a graph of ventricular diastolic dysfunction was evaluated in young WT and PAD4\(^{-/-}\) (6 - 8 weeks) mice as well as old WT and PAD4\(^{-/-}\) mice (15 - 20 months). The flow pattern across the mitral valve was assessed using Pulsed Wave Doppler mode and ventricular filling pattern was calculated as the ratio between the E and A wave. Only the old WT mice showed evidence of impaired ventricular relaxation with an average E/A ratio below 1. n = 4-6. **Fig. 6E** is characteristic images of Pulsed Wave Doppler measurements of the E and A wave showed a normal E’A pattern (E>A) in the old PAD4\(^{-/-}\) mice and a reversed pattern (E<A) in the old WT mice, leading to a ratio of under 1. *P < 0.05, **P < 0.01, ***P < 0.001.

**Figures 7A to 7D** are graphs and images indicating that PAD4-deficiency reduced age-related cardiac fibrosis: **Fig. 7A** is a graph of interstitial collagen, Cardiac interstitial fibrosis was assessed by Sirius Red staining for collagen fibers in sections of the left ventricle of the heart of WT and PAD4\(^{-/-}\) retired breeders (1217 months). The percentage of fibrotic area in the heart tissue was quantified by ImageJ shown in **Fig. 7C**, excluding perivascular fibrosis. In PAD4\(^{-/-}\) retired breeders, there was significantly less interstitial fibrosis than in WT retired breeders, n = 6. **Fig. 7B** is a graph showing interstitial collagen. The same analysis was performed for young (6-8 weeks) WT and young PAD4\(^{-/-}\) mice as well as for old (14-18 months) WT and old PAD4\(^{-/-}\) mice on standard diet. Quantification of Sirius red staining again showed less fibrosis in the old PAD4\(^{-/-}\) mice compared to the old WT mice. In old PAD4\(^{-/-}\) mice, the percentage of interstitial collagen remained comparable to young PAD4\(^{-/-}\) mice, n = 7-8. **Fig. 7C** are images, Sirius red staining of cardiac tissue showed more fibrotic strands in the myocardium of WT retired breeders compared to the PAD4\(^{-/-}\) retired breeders. Composite images of the left ventricle were generated using the ImageJ MosaicJ software; representative mosaics are presented. Scale bar = 100 \(\mu\)m. Arrowheads indicate stained collagen strands. **Fig. 7D** are images, the increase in myocardial interstitial collagen fibers in WT retired breeders compared to PAD4\(^{-/-}\) retired
breeders was more clearly visible at higher magnification in the Sirius red staining (left) and in Masson's trichrome stain for collagen (right, collagen fibers are blue (see arrows)). Scale bar = 100 μm. Arrowheads point to collagen fibers. *P < 0.05, **P < 0.01

**Figures 8A to 8C** are graphs and images, Old PAD4−/− mice have significantly less collagen staining in their lungs than old WT mice. **Fig. 8A** is a graph showing the percentage of collagen positive area in lung tissue of WT and PAD4−/− retired breeders (12-17 months) was quantified using Masson's trichrome stain for collagen and subsequently color gating for blue fibers. Retired WT breeders had a significantly higher percentage of collagen in lung tissue than retired PAD4−/− breeders, n = 6-7. **Fig. 8B** is a graph of interstitial collagen/lung tissue %; the same analysis for collagen fibers within the lung tissue was performed for young (6-8 weeks) WT and PAD4−/− mice and old (14-18 months) WT and PAD4−/− mice. While collagen content increased from young mice to old mice in both WT and PAD4−/− mice, this increase was significantly higher in the old WT mice, n = 4. **Fig. 8C** is a panel of representative photographs of lung sections stained with Masson's trichrome stain. Scale bar = 20 μm. *P < 0.05, **P <0.01, **** P <0.0001.

**Figures 9a to 9f** show graphs and images of the basic parameters of STZ-induced diabetes in WT and PAD4−/− mice. Mice were injected i.p. with vehicle or STZ (50 mg/kg per day) for 5 consecutive days. Body weight and fed blood glucose were examined starting 1 week after completion of injections. **Fig. 9a** is a graph of weight over time, STZ-treated mice gained less weight compared to the vehicle control. **Fig. 9b** is a graph of glucose over time. Diabetes was defined as fed blood glucose >300 mg/dL (indicated by blue dotted line). STZ-treated mice became diabetic the first week after treatment. (**Fig. 9a, Fig. 9b**) ***P<0.001 at all time points starting week 1 between vehicle and STZ. Student's t test, n = 15 for Vehicle, n = 13 for STZ. **Fig. 9c** is an image that validates diabetes induction. Representative immunofluorescence images showing a marked reduction of insulin-producing β cells and disrupted islet morphology in the pancreas of STZ-treated mice. **Fig. 9d,** and **Fig. 9e** PAD4−/− mice attained body weight (**Fig. 9d**) and fed blood glucose levels (**Fig. 9e**) similar to WT after STZ injection. AB indicates the period of antibiotic treatment (after wounding), which did not affect fed blood glucose levels in any group (**Fig. 9e**). (**Fig. 9d, Fig. 9e**) ***P<0.001 at all time points starting week 1 between WT vehicle and WT STZ, ###P<0.001 at all time points starting week 1 between PADS− vehicle and PADS− STZ. Student's t test, n = 7 for WT Vehicle, n = 9 for WT STZ, n = 5 for PAD4−/− Vehicle, n = 6 for
**PAD4**−/− STZ. Fig. 9f is a graph of percent mice induced to be diabetic. Chi-square test indicates no difference between WT and **PAD4**−/− in diabetes inducibility using STZ. P=1.00

**Figures 10a to 10b** are graphs of wound healing over time. Antibiotics do not abrogate the beneficial effect of **PAD4** deficiency on wound healing. Under antibiotic treatment, **PAD4**−/− mice still fared better in terms of (Fig. 10a) wound area reduction and (Fig. 10b) days required for total wound closure. *P<0.05, **P<0.01 between groups on the same day or between curves, Student's t test, n = 7 for WT Vehicle, n = 5 for **PAD4**−/− Vehicle.

**Figure 11** shows a graph of percent NETS. High glucose (HG) enhances PMA (100 nM)-stimulated NET formation in neutrophils isolated from healthy subjects compared to neutrophils exposed to normal glucose (NG) medium or mannitol (M), osmotic control. **P<0.01, repeated measures ANOVA, n = 5 per condition.

**Figure 12a and 12b** are Western blots and quantitative graphs indicating H3Cit (Fig.12a) is absent while neutrophil recruitment (Fig. 12b) is unaffected in wounds of **PAD4**−/− mice. Summarized Western blot data of Figure 3a +/+ WT; −/−, **PAD4**−/−. ***P<0.01 versus day 1 WT, ###P<0.001 versus WT on respective day, Student's t test, n = 5-8 for WT, n = 5-9 for **PAD4**−/−.

**Figure 13** is a schematic of chemical reactions to obtain peptidomimetic **PAD4** inhibitors useful in the instant invention, e.g. compounds 1-16. This figure was obtained from Trabocchi et al. *J. Enzyme Inhib. Med. Chem.*, early online 1-6 (2014): DOI: 10.3 109/147563662014947976, in order to illustrate compounds 1-16 described therein.

**Detailed Description**

**Definitions**

For convenience, the meaning of certain terms and phrases used in the specification, examples, and appended claims, are provided below. If there is an apparent discrepancy between the usage of a term in the art and its definition provided herein, the definition provided within the specification shall prevail.


Unless otherwise stated, the present invention was performed using standard labratoty techniques found, for example in the Molecular Cloning: A Laboratory Manual, 3rd Ed., Sambrook and Russel, Cold Spring Harbor Laboratory Press, 2001; or e.g. the latest edition of Methods in Enzymology Series. Editor: John Abelson, Melvin Simon, Anna Pyle, Elsevier Science Publishing Inc. New York.

The terms "decrease", "reduced", "reduction", "decrease" or "inhibit" are all used herein generally to mean a decrease by a statistically significant amount. However, for avoidance of doubt, ""reduced", "reduction" or "decrease" or "inhibit" means a decrease by at least 10% as compared to a reference level, e.g. in the absence of an agent, for example a decrease by at least about 20%, or at least about 30%, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%.

The terms "increased" or "increase" or "enhance" or "activate" are all used herein to generally mean an increase by a statically significant amount; for the avoidance of any doubt, the terms "increased", "increase" or "enhance" or "activate" means an increase of at least 10% as compared to a reference level, e.g. in the absence of an agent, for example an increase of at least about 20%, or at least about 30%, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%, or at least about a 2-fold, or at least about a 3-fold, or at least about a 4-fold, or at least about a 5-fold or at least about a 10-fold increase, or any increase between 2-fold and 10-fold or greater as compared to a reference level.

The term "statistically significant" or "significantly" refers to statistical significance and generally means a two standard deviation (2SD) below normal, or lower, concentration of the marker. The term refers to statistical evidence that there is a difference.
It is defined as the probability of making a decision to reject the null hypothesis when the null hypothesis is actually true. The decision is often made using the p-value.

[0061] Other than in the operating examples, or where otherwise indicated, all numbers expressing quantities of ingredients or reaction conditions used herein should be understood as modified in all instances by the term "about." The term "about" when used in connection with percentages can mean ±1%.

[0062] The singular terms "a," "an," and "the" include plural referents unless context clearly indicates otherwise. Similarly, the word "or" is intended to include "and" unless the context clearly indicates otherwise. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of this disclosure, suitable methods and materials are described below. The abbreviation, "e.g." is derived from the Latin exempli gratia, and is used herein to indicate a non-limiting example. Thus, the abbreviation "e.g." is synonymous with the term "for example."

[0063] All patents and other publications identified are expressly incorporated herein by reference for the purpose of describing and disclosing, for example, the methodologies described in such publications that might be used in connection with the present invention. These publications are provided solely for their disclosure prior to the filing date of the present application. Nothing in this regard should be construed as an admission that the inventors are not entitled to antedate such disclosure by virtue of prior invention or for any other reason. All statements as to the date or representation as to the contents of these documents is based on the information available to the applicants and does not constitute any admission as to the correctness of the dates or contents of these documents.

[0064] As used herein, the term "administer" refers to the placement of a composition into a subject by a method or route which results in at least partial localization of the composition at a desired site such that desired effect is produced. A compound or composition described herein can be administered by any appropriate route known in the art including, but not limited to, oral or parenteral routes, including intravenous, intramuscular, subcutaneous, transdermal, airway (aerosol), pulmonary, nasal, rectal, and topical (including buccal and sublingual) administration. In certain embodiments, the anti-NET compound is administered by local administration, e.g. local injection, or other method allowing delivery to a target site within an organ. As used herein, the term "local" means localized to the organ or wound, i.e. not systemic administration.
Some exemplary modes of administration include, but are not limited to, injection, infusion, instillation, inhalation, or ingestion. "Injection" includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intraventricular, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, sub capsular, subarachnoid, intraspinal, intracerebro spinal, and intrasternal injection and infusion. In preferred embodiments, the compositions are administered by intravenous infusion or injection.

As used herein, the term "antibody" refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site that immunospecifically bind an antigen. The terms also refers to antibodies comprised of two immunoglobulin heavy chains and two immunoglobulin light chains as well as a variety of forms besides antibodies; including, for example, Fv, Fab, and F(ab)2 as well as bifunctional hybrid antibodies (e.g., Lanzavecchia et al., Eur. J. Immunol. 17, 105 (1987)) and single chains (e.g., Huston et al., Proc. Natl. Acad. Sci. U.S.A., 85, 5879-5883 (1988) and Bird et al., Science 242, 423-426 (1988), which are incorporated herein by reference). (See, generally, Hood et al., Immunology, Benjamin, N.Y., 2ND ed. (1984), Harlow and Lane, Antibodies. A Laboratory Manual, Cold Spring Harbor Laboratory (1988) and Hunkapiller and Hood, Nature, 323, 15-16 (1986), which are incorporated herein by reference).

As used herein in the context of expression, the terms "treat," "treatment," "treating" and the like, in the context of the present invention insofar as it relates to any of the conditions recited herein (e.g. fibrosis, Diabetes (e.g. NET driven inflammation and delayed wound healing in Diabetes)), mean to relieve, alleviate, ameliorate, inhibit, slow down, reverse, or stop the progression, aggravation, deterioration, progression, anticipated progression or severity of at least one symptom or complication associated with such condition (e.g. fibrosis, Diabetes (e.g. NET driven inflammation and delayed wound healing in Diabetes)). In one embodiment, the symptoms of a condition are alleviated by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, or at least 50%.

By "lower" in the context of a disease marker or symptom is meant a statistically significant decrease in such level. The decrease can be, for example, at least 10%, at least 20%, at least 30%, at least 40% or more, and is preferably down to a level accepted as within the range of normal for an individual without such disorder.
As used herein, the phrase "therapeutically effective amount" or "effective dose" refers to an amount that provides a therapeutic benefit in the treatment, prevention, or management of a condition caused by NETS (e.g., fibrosis or inhibition of wound healing, or treatment of diabetes), e.g., an amount that provides a statistically significant decrease in at least one symptom of the condition (e.g., collagen deposition or slow wound healing, or inflammation of diabetes). Determination of a therapeutically effective amount is well within the capability of those skilled in the art. Generally, a therapeutically effective amount can vary with the subject's history, age, condition, sex, as well as the severity and type of the medical condition in the subject, and administration of other pharmaceutically active agents.

As used herein, the term "pharmaceutical composition" refers to the active agent in combination with a pharmaceutically acceptable carrier of chemicals and compounds commonly used in the pharmaceutical industry.

The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.

The phrase "pharmaceutically acceptable carrier" as used herein means a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting the subject agents from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation, for example the carrier does not decrease the impact of the agent on the treatment. In other words, a carrier is pharmaceutically inert.

As used herein, a "subject" means a human or animal. In one embodiment, the animal is a vertebrate such as a primate, rodent, domestic animal, avian species, fish or game animal. The terms, "patient", "individual" and "subject" are used interchangeably herein.

Preferably, the subject is a mammal. The mammal can be a human or non-human primate. Mammals other than humans can be advantageously used as subjects that represent animal models of fibrosis, wound healing or diabetic conditions. In addition, the methods described herein can be used to treat domesticated animals and/or pets.

The subject can be one who has been previously diagnosed with an organ fibrosis, or diabetes, or a subject identified as having one or more complications related to an
organ fibrosis or diabetes, and optionally, but need not have already undergone treatment for
the condition, or the one or more complications related to the condition.

[0076] A subject can also be one who is not suffering from the condition, e.g. fibrosis,
or diabetes. For example, a subject can be one who exhibits one or more risk factors for
fibrosis or diabetes; e.g. having a family history if the disease or being of older age, e.g. a
subject over 30 years of age, or over 40 years of age, or over 50 years of age. Accordingly,
methods for preventing the formation of organ fibrosis are also provided, the methods
comprise treating the subject determined to be at risk for fibrosis, with an anti-NET
compound. In certain embodiments, the patient at risk of fibrosis is at least 40 years of age,
at least 50 years of age, at least 60 years of age, or at least 70 years of age. In certain
embodiments, the patient at risk of fibrosis is a patient that is to be exposed to radiation, e.g. a
patient of any age.

**NETosis**

[0077] Embodiments of the technology described herein are based, in part, on the
discovery that NETosis in a subject slows the wound healing process and that NETosis is
linked with collagen deposition in organ fibrosis. It has also been determined herein that
increased NETosis is present in Diabetes.

[0078] As used herein, the term "NET" refers to extracellular complexes of
nucleosomes and proteins, e.g. proteins having anti-microbial activity. The nucleosomes may
be derived from neutrophils, mast cells, eosinophils, monocytes, or leukocytes. "NETosis"
refers to the formation of NETS through a unique form of cell death that is characterized by
the release of decondensed chromatin and granular contents to the extracellular space.

[0079] Herein, we have determined that NETosis is elevated in wounds and in
subjects that have diabetes. We have further determined that NETosis is prominent in aging
and have found a connection between the prevalence of NETosis and organ fibrosis. In
particular, we have determined that peptidylarginine deiminase 4 (PAD4), a key enzyme
needed for the formation of NETS, promotes age related organ fibrosis. Thus, methods for
treating wounds, diabetes and fibrosis are provided. The methods comprise administrating a
therapeutically effective amount of at least one anti-NET compound (e.g. a PAD 4 inhibitor;
a DNase, a histone-degrading enzyme; an inhibitor of chromatin decondensation; an antibody
against a component of a NET; a protease inhibitor, or an elastase inhibitor, or protease
inhibitor) to a subject in need of treatment.

*Anti-NET Compounds*
Some embodiments are directed to methods for the treatment or prevention of organ fibrosis, or NET associated complications in diabetes (e.g. increased inflammation and delayed wound healing), in a patient with anti-NET compound. Other embodiments are directed to methods for facilitating wound healing in a subject comprising administering an anti-NET compound. In certain embodiments the anti-NET compounds are delivered directly to the wound. As used herein, "anti-NET compounds" can include any compound that degrades or targets for degradation any component of a NET and/or that prevents the formation of NETs (e.g. PAD4 inhibitors). Also included are compounds that otherwise inhibit the activity of a NET component or impair the ability of a cell to form a NET, e.g. inhibition of PAD4, which is required for NET formation. An anti-NET compound can be a nucleic acid (DNA or RNA), small molecule, lipid, carbohydrate, protein, peptide, antibody, or antibody fragment. In some embodiments, an anti-NET compound is an enzyme, e.g. an enzyme which cleaves and/or degrades, e.g. a nucleic acid, protein, polypeptide, or carbohydrate.

As used herein, the term "small molecule" refers to a chemical agent which can include, but is not limited to, a peptide, a peptidomimetic, an amino acid, an amino acid analog, a polynucleotide, a polynucleotide analog, an aptamer, a nucleotide, a nucleotide analog, an organic or inorganic compound (i.e., including heteroorganic and organometallic compounds) having a molecular weight less than about 10,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 5,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 1,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 500 grams per mole, and salts, esters, and other pharmaceutically acceptable forms of such compounds.

In certain embodiments an anti-NET compound is selected from the group consisting of; DNase, heparin, an antibody (i.e. an antibody to histones or to a particular histone), a histone degrading enzyme (i.e. mast cell proteinase 1 (Gene ID: 1215)), plasmin (Gene ID: 5340), cathepsin D (Gene ID: 1509) or activated protein C (Gene ID:5624)) or an inhibitor of chromatin decondensation (i.e.staurosporine, HDAC inhibitors (i.e. M344), PAD4 inhibitors, protease inhibitors, or elastase inhibitors (i.e. Gelin®)).

In one embodiment, the anti-NET compound is not heparin. In one embodiment, the anti-NET compound is not DNase. In some embodiments, the anti-NET compound is selected from the group consisting of; a histone-degrading enzyme; an inhibitor
of chromatin decondensation; an antibody against a component of a NET; a protease inhibitor, an elastase inhibitor; or a PAD4 inhibitor.

[0084] Anti-NET compounds can be produced recombinantly using methods well known to those of skill in the art (See Sambrook et al., Molecular Cloning: A Laboratory Manual (2 ed.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., USA (1989)). Alternatively, anti-NET compounds are available commercially e.g. Pulmozyme® (Genentech; San Francisco, California), DNase (#D5319 Sigma-Aldrich; St. Louis, MO)#90083 Thermo Scientific; Rockford, IL), RNAse (#R4642 Sigma-Aldrich; St. Louis, MO), Heparin® (Celsius; Cincinatti, OH), anti-histone antibodies (abl791, ab8580, ab8898, ab6002, abl790, ab9053, abl0158, ab71594, ab4269 Abeam; Cambridge, MA), mast cell proteinase 1 (5146-SE-010 R&D Systems; Minneapolis, MN), thrombin (HCT-0020 Haematologic Technologies; Essex Junction, VT), plasmin (HCPM-0140 Haematologic Technologies; Essex Junction, VT), cathepsin D (1014-AS-010 R&D Systems; Minneapolis, MN), activated protein C (AEZ004B Aniara; Mason, OH), staurosporine (S4400 Sigma-Aldrich; St. Louis, MO), M344 (M5820 Sigma-Aldrich; St. Louis, MO) or Gelin® (G0528 Sigma-Aldrich; St. Louis, MO).

[0085] In certain embodiments, the anti-NET compound is a monoclonal antibody (See, generally, Hood et al., Immunology, Benjamin, N.Y., 2ND ed. (1984), Harlow and Lane, Antibodies. A Laboratory Manual, Cold Spring Harbor Laboratory (1988) and Hunkapiller and Hood, Nature, 323, 15-16 (1986), which are incorporated herein by reference).

[0086] In some embodiments, the anti-NET agent is a PAD4 inhibitor. As used herein, "PAD4" refers to peptidylarginine deiminase 4, an enzyme that converts protein arginine residues to citrulline through a deimination reaction (e.g. SEQ ID NO: 01 (mRNA) and SEQ ID NO: 02 (protein)).

[0087] In certain embodiments, the anti-NET agent is a general PAD inhibitor, i.e. is an inhibitor that inhibits more than one type of PAD enzyme, e.g. PAD1, and/or PAD2, and/or PAD3 or, and/or PAD4. See e.g. Wang et al., Anticancer peptidylarginine deiminase (PAD) inhibitors regulate the autophagy flux and the mammalian target of rapamycin complex 1 activity J Biol Chem. 2012 Jul 27;287(31):25941-53; e.g. YW3-56. See also PCT Publication WO/2014/188193 entitled 'peptidylarginine deiminases (pad) inhibitors.'

[0088] PAD4 is distinguished from other PAD family enzymes by having a nuclear localization signal and thus being able to enter the nucleus and citrullinate histones. As
described herein, a loss of PAD4 activity results in decreased NET formation and decreased DVT in mice. A PAD4 inhibitor can decrease the expression or activity of PAD4.

Inhibition of PAD4 can be monitored by measuring PAD4 activity. A non-limiting example of an assay of PAD4 activity is as follows: a candidate inhibitor, in a reaction buffer comprising 100 mM HEPES (pH 7.6), 50 mM NaCl, and 0.5 mM tris(2-carboxyethyl)diphosphine (TCEP) can be preincubated with PAD4 (0.2 µM) (in the presence or absence of 10 mM CaCl2) at 37°C for 15 min prior to the addition of the substrate, N-acetyl-L-arginine ethyl ester (BAEE) (10 mM final concentration) (and 10 mM CaCl2 if CaCl2 was absent in the pre-incubation) to initiate the reaction. After 15 min the reactions can be quenched by flash freezing in liquid nitrogen. For color development, 200 µL of freshly prepared Coldter solution (2.25 M H3PO4, 4.5 M H2SO4, 1.5 mMNH₄Fe(SO₄), 20 mM diacetyl monoxime, and 1.5 mM thiosemicarbazide) can be added to each of the quenched reactions, vortexed to ensure complete mixing, and then incubated at 95°C for 30 minutes. The absorbance at 540 nm can then be measured and compared to a citrulline standard curve to determine the concentration of citrulline produced during the course of the reactions (PAD4 deiminates the BAEE substrate). IC50 values can be determined by fitting the concentration-response data to Eq. (1)

Fractional activity of PAD4 = 1/(1+([candidate inhibitor]/IC50)) (Eq. 1)

The concentration of an inhibitor that corresponds to the midpoint (fractional activity = 0.5) can be referred to as the IC50. Kits for measuring PAD4 activity are also commercially available, e.g. Cat No. 7000560, Cayman Chemical; Ann Arbor, MI.

Any inhibitors of PAD4 can be used in the methods described herein. For example, in some embodiments, a PAD4 inhibitor can be a small molecule inhibitor. Small molecule inhibitors of PAD4 are known in the art (see, for example, Luo et al. Biochemistry 2006; U.S. Patent 7,964,636; and U.S. Patent Publications 2007/0276040 and 201 1/0142868; each of which is incorporated by reference herein in its entirety) and include, by way of non-limiting example, Cl-amidine and F-amidine. In some embodiments, the PAD4 inhibitor can be specific for PAD4. In some embodiments, the PAD4 inhibitor can be a PAD family inhibitor. PAD4 inhibitors are commercially available, e.g. Cl-amidine (Catalog number 10599, CAS 913723-61-2, Cayman Chemical; Ann Arbor, MI) and F-amidine (Catalog number 10610; Cayman Chemica; Ann Arbor, MI).

As used herein, "Cl-amidine" refers to a compound having the structure of formula 1:
As used herein, "Fl-amidine" refers to a compound having the structure of formula II:

[0095] In some embodiments, the PAD4 inhibitor can be an antibody, a polypeptide comprising a fragment of an antibody, or a nucleic acid. Antibodies, and methods of making them are described above herein.

[0096] In certain embodiments, the inhibitors are selective PAD4 inhibitors that are reversible, e.g. including but not limited to GSK484 and GSK199 (Nat. Chem. Biology, in Press).

[0097] In certain embodiments, the PAD4 inhibitor is a tetrazole analog, e.g. as described in Subramanian et al., Design, synthesis and biological evaluation of tetrazole analogs of Cl-amidine as protein arginine deiminase inhibitors J. Med. Chem., DOI: 10.1021/jm501636x Publication Date (Web): January 5, 2015.

[0098] In one embodiment the tetrazole analog is biphenyl tetrazole tert-butyl Cl-amidine (BTT-Cl-amidine) that exhibits enhanced cell killing in a PAD4 expressing cells also blocks the formation of neutrophil extracellular traps (Subramanian et al., Supra).

[0099] In certain embodiments, the PAD4 inhibitor is a peptidomimetic compound, e.g. including but not limited to 1,2,3-triazole peptidomimetic based derivatives incorporating beta-phenylalanine and guanidine scaffolds, e.g. as described in Trabocchi et al.
Peptidomimetics as protein arginine deiminase 4 (PAD4) inhibitors, *J. Enzyme Inhib. Med. Chem.*, early online 1-6 (2014); DOI: 10.3 109/147563662014947976. See also Figure 13 that illustrates chemistry for 16 peptidomimetic PAD4 inhibitors as described in Trabocchi et al. *Supra*, e.g. 1,2,3-triazole peptidomimetic based derivatives.

In certain embodiments, the anti-NET compound is an inhibitor of NET release from cells, e.g. Cl-amidine blocks NET release from NZM neutrophils in vitro, other inhibitors of NET release are known to those of skill in the art.


In certain embodiments, the PAD4 inhibitor is YW3-56, as described in Wang et al., (2012) *J. Biol. Chem* 287(3 1):25941-53.

PAD4 inhibitors which comprise a nucleic acid can be RNAi agents and/or gene silencing agents. As used herein, "gene silencing" or "gene silenced" in reference to an activity of an RNAi molecule, for example a siRNA or miRNA refers to a decrease in the mRNA level in a cell for a target gene by at least about 5%, about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, about 99% or more of the mRNA level found in the cell without the presence of the miRNA or RNA interference molecule. In one preferred embodiment, the mRNA levels are decreased by at least about 70%, about 80%, about 90%, about 95%, about 99% or more.

As used herein, the term "RNAi" refers to any type of interfering RNA, including but are not limited to, siRNAi, shRNAi, endogenous microRNA and artificial microRNA. For instance, it includes sequences previously identified as siRNA, regardless of the mechanism of down-stream processing of the RNA (i.e. although siRNAs are believed to have a specific method of in vivo processing resulting in the cleavage of mRNA, such sequences can be incorporated into the vectors in the context of the flanking sequences described herein). The term "RNAi" and "RNA interfering" with respect to an agent of the invention, are used interchangeably herein.

As used herein an "siRNA" refers to a nucleic acid that forms a double stranded RNA, which double stranded RNA has the ability to reduce or inhibit expression of a gene or target gene when the siRNA is present or expressed in the same cell as the target gene, sEH. The double stranded RNA siRNA can be formed by the complementary strands.
In one embodiment, a siRNA refers to a nucleic acid that can form a double stranded siRNA. The sequence of the siRNA can correspond to the full length target gene, or a subsequence thereof. Typically, the siRNA is at least about 15-50 nucleotides in length (e.g., each complementary sequence of the double stranded siRNA is about 15-50 nucleotides in length, and the double stranded siRNA is about 15-50 base pairs in length, preferably about 19-30 base nucleotides, preferably about 20-25 nucleotides in length, e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides in length).

As used herein "shRNA" or "small hairpin RNA" (also called stem loop) is a type of siRNA. In one embodiment, these shRNAs are composed of a short, e.g. about 19 to about 25 nucleotide, antisense strand, followed by a nucleotide loop of about 5 to about 9 nucleotides, and the analogous sense strand. Alternatively, the sense strand can precede the nucleotide loop structure and the antisense strand can follow.

The terms "microRNA" or "miRNA" are used interchangeably herein are endogenous RNAs, some of which are known to regulate the expression of protein-coding genes at the posttranscriptional level. Endogenous microRNA are small RNAs naturally present in the genome which are capable of modulating the productive utilization of mRNA. The term artificial microRNA includes any type of RNA sequence, other than endogenous microRNA, which is capable of modulating the productive utilization of mRNA. MicroRNA sequences have been described in publications such as Lim, et al., Genes & Development, 17, p. 991-1008 (2003), Lim et al Science 299, 1540 (2003), Lee and Ambros Science, 294, 862 (2001), Lau et al., Science 294, 858-861 (2001), Lagos-Quintana et al, Current Biology, 12, 735-739 (2002), Lagos Quintana et al, Science 294, 853-857 (2001), and Lagos-Quintana et al, RNA, 9, 175-179 (2003), which are incorporated by reference. Multiple microRNAs can also be incorporated into a precursor molecule. Furthermore, miRNA-like stem-loops can be expressed in cells as a vehicle to deliver artificial miRNAs and short interfering RNAs (siRNAs) for the purpose of modulating the expression of endogenous genes through the miRNA and or RNAi pathways.

As used herein, "double stranded RNA" or "dsRNA" refers to RNA molecules that are comprised of two strands. Double-stranded molecules include those comprised of a single RNA molecule that doubles back on itself to form a two-stranded structure. For example, the stem loop structure of the progenitor molecules from which the single-stranded miRNA is derived, called the pre-miRNA (Bartel et al. 2004. Cell 116:281-297), comprises a dsRNA molecule.
As used herein, the term "complementary" or "complementary base pair" refers to A:T and G:C in DNA and A:U in RNA. Most DNA consists of sequences of nucleotide only four nitrogenous bases: base or base adenine (A), thymine (T), guanine (G), and cytosine (C). Together these bases form the genetic alphabet, and long ordered sequences of them contain, in coded form, much of the information present in genes. Most RNA also consists of sequences of only four bases. However, in RNA, thymine is replaced by uridine (U).

As used herein, the term "nucleic acid" or "nucleic acid sequence" refers to any molecule, preferably a polymeric molecule, incorporating units of ribonucleic acid, deoxyribonucleic acid or an analog thereof. The nucleic acid can be either single-stranded or double-stranded. A single-stranded nucleic acid can be one strand nucleic acid of a denatured double-stranded DNA. Alternatively, it can be a single-stranded nucleic acid not derived from any double-stranded DNA. In one aspect, the template nucleic acid is DNA. In another aspect, the template is RNA. Suitable nucleic acid molecules are DNA, including genomic DNA, ribosomal DNA and cDNA. Other suitable nucleic acid molecules are RNA, including mRNA, rRNA and tRNA. The nucleic acid molecule can be naturally occurring, as in genomic DNA, or it may be synthetic, i.e., prepared based on human action, or may be a combination of the two. The nucleic acid molecule can also have certain modification such as 2'-deoxy, 2'-deoxy-2'-fluoro, 2'-0-methyl, 2'-0-methoxyethyl (2'-0-MOE), 2'-0-aminopropyl (2'-0-AP), 2'-0-dimethylaminoethyl (2'-0-DMAOE), 2'-0-dimethylaminopropyl (2'-0-DMAP), 2'-0-dimethylaminoethylxyethyl (2'-0-DMAEOE), or 2'-0-N-methylacetamido (2'-O-NMA), cholesterol addition, and phosphorothioate backbone as described in US Patent Application 20070213292; and certain ribonucleoside that are is linked between the 2'-oxygen and the 4'-carbon atoms with a methylene unit as described in US Pat No. 6,268,490, wherein both patent and patent application are incorporated hereby reference in their entirety.

In some embodiments, a nucleic acid which is or which encodes a PAD4 inhibitor further comprises a vector. The term "vector", as used herein, refers to a nucleic acid construct designed for delivery to a host cell or for transfer between different host cells. As used herein, a vector can be viral or non-viral. The term "vector" encompasses any genetic element that is capable of replication when associated with the proper control elements and that can transfer gene sequences to cells. A vector can include, but is not limited to, a cloning vector, an expression vector, a plasmid, phage, transposon, cosmide, chromosome, virus, virion, etc.
As used herein, the term "expression vector" refers to a vector that directs expression of an RNA or polypeptide from sequences linked to transcriptional regulatory sequences on the vector. The sequences expressed will often, but not necessarily, be heterologous to the cell. An expression vector may comprise additional elements, for example, the expression vector may have two replication systems, thus allowing it to be maintained in two organisms, for example in human cells for expression and in a prokaryotic host for cloning and amplification. As used herein, the term "viral vector" refers to a nucleic acid vector construct that includes at least one element of viral origin and has the capacity to be packaged into a viral vector particle. The viral vector can contain the PAD4 inhibitor in place of non-essential viral genes. The vector and/or particle may be utilized for the purpose of transferring any nucleic acids into cells either in vitro or in vivo. Numerous forms of viral vectors are known in the art. Vectors useful in the methods described herein can include, but are not limited to, plasmids, retroviral vectors, adenoviral vectors, adeno-associated viral vectors, and pox virus vectors.

The term "replication incompetent" when used in reference to a viral vector means the viral vector cannot further replicate and package its genomes. For example, when the cells of a subject are infected with replication incompetent recombinant adeno-associated virus (rAAV) virions, the heterologous (also known as transgene) gene is expressed in the patient's cells, but, the rAAV is replication defective (e.g., lacks accessory genes that encode essential proteins for packaging the virus) and viral particles cannot be formed in the patient's cells. The term "transduction" as used herein refers to the use of viral particles or viruses to introduce exogenous nucleic acids into a cell. The term "transfection" as used herein in reference to methods, such as chemical methods, to introduce exogenous nucleic acids, such as the nucleic acid sequences encoding an agent which decreases the activity and/or level of PAD4 as described herein, into a cell. As used herein, the term transfection does not encompass viral-based methods of introducing exogenous nucleic acids into a cell. Methods of transfection include physical treatments (electroporation, nanoparticles, magnetofection), and chemical-based transfection methods. Chemical-based transfection methods include, but are not limited to those that use cyclodextrin, polymers, liposomes, nanoparticles, cationic lipids or mixtures thereof (e.g., DOPA, Lipofectamine and UptiFectin), and cationic polymers, such as DEAE-dextran or polyethylenimine.
[00114] Methods of making RNAi agents which inhibit the expression and/or activity of PAD4 are well known in the art. Sequences complementary to the mRNA encoding PAD4 (i.e. SEQ ID NO: 1) can be used to design RNAi agents as described above herein.

[00115] The disruption of NETs can be monitored in vivo or in vitro. In one embodiment, the disruption of NETs is monitored by assessing the level of NET release in stored blood in the presence and absence of a test compound, e.g. by ELISA and/or determination of DNA concentration as described herein. In one embodiment, the ability of a test compound to disrupt NETs is monitored in vivo, e.g. by determining the ability to prevent platelet adhesion and aggregation.

Methods of Treatment

[00116] Described herein are methods of treating conditions such as diabetes (e.g. NET associated inflammation and delayed wound healing in diabetes), fibrosis, and skin wounds. As determined herein, these conditions are associated with an increased NETosis, and thus NETs can be targeted for treatment of these disorders.

[00117] In one embodiment, a method of treating or preventing organ fibrosis in a subject is provided. The method comprises administering to a subject in need of treatment, a therapeutically effective amount of at least one anti-NET compound.

[00118] As used herein "Organ fibrosis" refers to fibrotic deposition that can occur in any organ. Fibrotic deposition (fibrosis) is a pathological condition characterized by excessive synthesis and accumulation of extracellular matrix proteins, loss of tissue homeostasis and organ failure.

[00119] As used herein "age-related organ fibrosis" refers to fibrosis that occurs in organs that has not been associated with any underlying disease, i.e. fibrosis occurring as a consequence of aging, e.g. idiopathic organ fibrosis, a non-limiting example; idiopathic pulmonary fibrosis (IPF).

[00120] As used herein, the term "preventing" as it relates to fibrosis refers to inhibition of interstitial collagen deposition. In one embodiment, the deposition of collagen is decreased by at least 10%, at least 20%, at least 30%, at least 40%, or at least 50%. Deposition of collagen can be determined using methods well known to those of skill in the art, e.g. as described in Example 2, or by monitoring mRNA (See e.g. Casey et al. (1996) Biology of Reproduction, 55, 1253-1260). Collagen deposition can also be monitored using histology assays, e.g. in tissue samples. Collagen antibodies are commercially available from
Rockland immunochemical corporation (Limerick, PA) e.g., COLLAGEN Type I Antibody 600-401-103-0.5, or from Santa Cruz Biotechnology (Dallas, Texas).

[00121] As used herein, "treating" as it relates to organ fibrosis refers to reducing at least one measurable symptom of organ fibrosis. In one embodiment, the measurable symptom is loss of organ function. Accordingly, in certain embodiments, the symptoms of fibrosis are dependent upon the organ affected, e.g. kidney, liver, heart, lung. Those of skill in the art are well versed in detecting proper organ function. Non limiting examples include assessing blood to determine kidney glomerular filtration rate (kidney function), or level of liver enzymes (liver function), or determine levels of oxygen and CO₂ in the blood (lung function); or performing e.g. echocardiograms, or EKG's of the heart, in the case of e.g. age related fibrosis of the heart. Techniques for measuring organ function are standard in the art. In certain embodiments, organ function is increased or improved by least 10%, at least 20%, at least 30%, at least 40%, or at least, 50% as compared to function prior to treatment with the anti-NET compound.

[00122] Methods for diagnosis of fibrosis are well known and include for example examination of tissue sections for collagen deposition, imaging studies, and assessment of organ function.

Diabetes

[00123] Also provided are methods for treating NET associated complications in diabetes (e.g inflammation and delayed wound healing). The methods comprise administering a therapeutically effective amount of at least one anti-NET compound. In some embodiments, the subject has been diagnosed with Type 1, Type 1.5 or Type 2 diabetes, or has been determined to have a pre-diabetic condition.

[00124] The terms "diabetes" and "diabetes mellitus" are used interchangeably herein. A "pre-diabetic condition" refers to a metabolic state that is intermediate between normal glucose homeostasis, metabolism, and states seen in frank Diabetes Mellitus. Pre-diabetic conditions include, without limitation, Metabolic Syndrome ("Syndrome X"), Impaired Glucose Tolerance (IGT), and Impaired Fasting Glycemia (IFG). IGT refers to post-prandial abnormalities of glucose regulation, while IFG refers to abnormalities that are measured in a fasting state. The World Health Organization defines values for IFG as a fasting plasma glucose concentration of 6.1 mmol/L (100 mg/dL) or greater (whole blood 5.6 mmol/L; 100 mg/dL), but less than 7.0 mmol/L (126 mg/dL)(whole blood 6.1 mmol/L; 110 mg/dL).

Metabolic Syndrome according to National Cholesterol Education Program (NCEP) criteria
are defined as having at least three of the following: blood pressure 130/85 mm Hg or higher; fasting plasma glucose 6.1 mmol/L or higher; waist circumference >102 cm (men) or >88 cm (women); triglycerides 1.7 mmol/L or higher; and HDL cholesterol <1.0 mmol/L (men) or 1.3 mmol/L (women).

Type 1 diabetes is an autoimmune disease that results in destruction of insulin-producing beta cells of the pancreas. Lack of insulin causes an increase of fasting blood glucose (around 70-120 mg/dL in nondiabetic people) that begins to appear in the urine above the renal threshold (about 190-200 mg/dl in most people). The World Health Organization defines the diagnostic value of fasting plasma glucose concentration to 7.0 mmol/l (126 mg/dl) and above for Diabetes Mellitus (whole blood 6.1 mmol/l or 110 mg/dl), or 2-hour glucose level of 11.1 mmol/L or higher (200 mg/dL or higher).

Type 1 diabetes can be diagnosed using a variety of diagnostic tests that include, but are not limited to, the following: (1) glyceded hemoglobin (AIC) test, (2) random blood glucose test and/or (3) fasting blood glucose test.

The Glycated hemoglobin (AIC) test is a blood test that reflects the average blood glucose level of a subject over the preceding two to three months. The test measures the percentage of blood glucose attached to hemoglobin, which correlates with blood glucose levels (e.g., the higher the blood glucose levels, the more hemoglobin is glycated). An AIC level of 6.5 percent or higher on two separate tests is indicative of diabetes. A result between 6 and 6.5 percent is considered prediabetic, which indicates a high risk of developing diabetes.

The Random Blood Glucose Test comprises obtaining a blood sample at a random time point from a subject suspected of having diabetes. Blood glucose values can be expressed in milligrams per deciliter (mg/dL) or millimoles per liter (mmol/L). A random blood glucose level of 200 mg/dL (11.1 mmol/L) or higher indicates the subject likely has diabetes, especially when coupled with any of the signs and symptoms of diabetes, such as frequent urination and extreme thirst.

For the fasting blood glucose test, a blood sample is obtained after an overnight fast. A fasting blood glucose level less than 100 mg/dL (5.6 mmol/L) is considered normal. A fasting blood glucose level from 100 to 125 mg/dL (5.6 to 6.9 mmol/L) is considered prediabetic, while a level of 126 mg/dL (7 mmol/L) or higher on two separate tests is indicative of diabetes. Type 1 diabetes can be distinguished from type 2 diabetes using a C-peptide assay, which is a measure of endogenous insulin production. The presence
of anti-islet antibodies (to Glutamic Acid Decarboxylase, Insulinoma Associated Peptide-2 or insulin), or lack of insulin resistance, determined by a glucose tolerance test, is also indicative of type 1, as many type 2 diabetics continue to produce insulin internally, and all have some degree of insulin resistance.

[00130] Testing for GAD 65 antibodies has been proposed as an improved test for differentiating between type 1 and type 2 diabetes as it appears that the immune system is involved in Type 1 diabetes etiology. Type 1.5 (also known as LADA Diabetes) is performed by determining the presence of anti-LADA antibodies.

[00131] Each of the diabetic conditions have overlapping symptoms. Exemplary symptoms of diabetes include, but are not limited to, excessive thirst (polydipsia), frequent urination (polyuria), extreme hunger (polyphagia), extreme fatigue, weight loss, hyperglycemia, low levels of insulin, high blood sugar (e.g., sugar levels over 250 mg, over 300 mg), presence of ketones present in urine, fatigue, dry and/or itchy skin, blurred vision, slow healing cuts or sores, more infections than usual, numbness and tingling in feet, diabetic retinopathy, diabetic nephropathy, blindness, memory loss, renal failure, cardiovascular disease (including coronary artery disease, peripheral artery disease, cerebrovascular disease, atherosclerosis, and hypertension), neuropathy, autonomic dysfunction, hyperglycemic hyperosmolar coma, and combinations thereof.

[00132] A therapeutically effective amount of an anti-NET compound is the amount of a compound administered to a subject that is sufficient to produce a statistically significant, measurable change in a symptom of Type 1, Type 1.5 or Type 2 diabetes that has NET involvement, e.g. increased inflammation or delayed wound healing.

[00133] In certain embodiments, the symptom of diabetes that has NET involvement is ameliorated by at least 10%, at least 20%, at least 30%, at least 40%, or at least 50%, as compared to the symptom prior to treatment with the anti-NET compound.

[00134] In certain embodiments, the symptom of diabetes having NET involvement is delay of wound healing.

[00135] In certain embodiments, the symptom of diabetes having NET involvement is inflammation. Reduction in inflammation can be monitored by physical examination, as well as the reduction in the presence of inflammatory markers. Acute inflammatory markers known to the person skilled in the art include C-reactive protein (CRP), fibrinogen, D-dimer, serum amyloid A (SAA), pregnancy-associated polypeptide A (PAPP-A), intercellular adhesion molecules (e.g. ICAM-1, VCAM-1), IL-1-beta, IL-6, IL-8, IL-17 IL-18/IL-18b;
TNF-alpha; myeloperoxidase (MPO); TF; monocyte chemoattractant protein 1 (MCP-1); P-selectin; E-selectin; platelet activating factor acetyl hydrolase (PAF-AH); von Willebrand Factor (vWF). Preferred markers of acute inflammation for use in a method described herein are CRP, fibrinogen, D-dimer and SAA, of which CRP and D-dimer are more preferably used. D-Dimer is a marker of thrombolysis and its generation may be NET-dependent.

In certain embodiments, a method for treatment of diabetes is provided that comprises the administration of a therapeutically effective amount of an agent used to treat diabetes and at least one anti-NET compound. In one embodiment, the agent used to treat diabetes is insulin. Other agents used to treat diabetes include, but are not limited to, Biguanides, Metformin (Glucophage), Metformin liquid (Riomet), Metformin extended release (Glucophage XR, Fortamet, Glumetza), Sulfonylureas, Glimepiride (Amaryl), Glyburide (Diabeta, Micronase), Glipizide (Glucotrol, Glucotrol XL), Micronized glyburide (Glynase), Meglitinides, Repaglinide (Prandin), D-Phenylalanine Derivatives, Nateglinide (Starlix), Thiazolidinediones, Pioglitazone (TZDs), Pioglitazone, (Actos), DPP-4 Inhibitor, Sitagliptin (Januvia), Saxagliptin (Onglyza), Linagliptin (Tradjenta), Alpha-glucosidase, Acarbose (Precose), Miglitol (Glyset), Bile Acid Sequestrants, Colesevelam (Welchol), Pioglitazone & metformin (Actoplus Met), Glyburide & metformin (Glucovanace), Glipizide & metformin (Metaglip), Sitagliptin & metformin (Janumet), Saxagliptin & metformin (kombiglyze), Repaglinide & metformin (Prandimet) and, Pioglitazone & glimepiride (Duetact).

Wound healing

Also provided are methods for treatments of wounds. In certain embodiments the patient that is administered an anti-net compound for the treatment of wounds, has previously been diagnosed with diabetes.

As used herein "wound healing" refers to the intricate process where the skin (or another organ-tissue) repairs itself after injury. The classic model of wound healing is divided into three or four sequential, yet overlapping, phases: (1) hemostasis, when clot stops bleeding, (2) inflammation, (3) proliferation and (4) remodeling. Upon injury to the skin, a set of complex biochemical events takes place in a closely orchestrated cascade to repair the damage (See e.g., Stadelmann, WK; Digenis, AG; Tobin, GR (1998). "Physiology and healing dynamics of chronic cutaneous wounds". American journal of surgery 176 (2A Suppl): 26S-38S). During the inflammation phase, bacteria and cell debris are phagocytosed and removed from the wound by white blood cells. Platelet-derived growth factors (stored in the alpha
granules of the platelets) are released into the wound that cause the migration and division of cells during the proliferative phase. The proliferation phase is characterized by angiogenesis, collagen deposition, granulation tissue formation, epithelialization, and wound contraction (Midwood, K.S.; (2004). "Tissue repair and the dynamics of the extracellular matrix". The International Journal of Biochemistry & Cell Biology 36 (6): 1031-1037). New blood vessels are formed and fibroblasts grow and form a new, provisional extracellular matrix (ECM) by excreting collagen and fibronectin. Concurrently, re-epithelialization of the epidermis occurs, in which epithelial cells proliferate and 'crawl' atop the wound bed, providing cover for the new tissue.

The growth of tissue around the wound site is a result of the migration of cells and collagen deposition by these cells. The alignment of collagen describes the degree of scarring; basket-weave orientation of collagen is characteristic of normal skin, whereas aligned collagen fibers lead to significant scarring.

As used herein the term "facilitating wound healing" refers to an acceleration the process of normal wound healing and/or inhibiting the amount of formation of scar tissue that occurs from the wound healing process.

In certain embodiments, effective treatment can also be determined by measuring the diameter of the wound over time. In certain embodiments, the diameter of the wound is decreased by at least 10%, at least 20%, at least 30%, at least 40%, or at least 50%/per unit time as compared to the diameter decrease per unit time usually observed in patients in the process of wound healing.

In certain embodiments, the formation of scar tissue is reduced by at least 10%, at least 20%, at least 30%, at least 40%, or at least 50%, as compared to an expected healing process in the absence of the anti-NET compound.

In certain embodiments, the anti-NET compound is provided in a pharmaceutically acceptable carrier that is time released, or that is integrated in a skin graft, or delivery device.

In certain embodiments, the treatment of a wound is assessed by monitoring dissolution of NETS in the wound.

Some embodiments relate to the use of at least one anti-NET compound and compositions containing at least one such anti-NET compound for the treatment of diabetes, treatment of fibrosis, or for facilitating wound healing. A composition containing an anti-
NET compound is used to reduce the severity, duration, or number of symptoms associated with the condition to be treated.

[00146] In one embodiment, a single administration of an anti-NET compound decreases the level of an indicator, symptom, or marker of fibrosis by at least 10%, e.g., by at least 20%, at least 30%, at least 50%, at least 75%, at least 90%, at least 95%, at least 99% or more as compared to the level of the indicator, symptom, or marker of a cardiovascular condition prior to treatment with the anti-NET compound.

[00147] In certain embodiments, a single administration of an anti-NET compound to a patient decreases the deposition of interstitial collagen in the patient's organ by at least 10%, e.g., by at least 20%, at least 30%, at least 50%, at least 75%, at least 90%, at least 95%, at least 99% or more as compared to the presence of collagen in the absence of treatment with the anti-NET compound.

[00148] In one embodiment, a single administration of an anti-NET compound to a group of patients facilitates wound healing by at least 10%, e.g., by at least 20%, by at least 30%, at least 50%, at least 75%, at least 90%, at least 95%, at least 99%, or more as compared to the rate of wound healing in a group of patients not administered the anti-NET compound.

[00149] The methods described herein relate to the use of at least one anti-NET compound or a pharmaceutical composition for treatment. In certain embodiments the at least one anti-NET compound is administered as a prophylactic, i.e. a patient exhibiting symptoms, markers, or indications of a condition described herein can be treated with at least one anti-NET compound in order to prevent or reverse the progression of the condition or to lessen the severity of future symptoms, markers, or indicators of the condition.

[00150] In certain embodiments the methods provided herein involve the use of at least one anti-NET compound. In further embodiments, the method provided herein involves the use of two or more anti-NET compounds, non limiting examples -a PAD4 inhibitor and a DNase.

[00151] In certain embodiments, the effective dose of at least one anti-NET compound is administered to a patient repeatedly.

[00152] In certain embodiments, administering a single dose of an anti-NET compound to a patient decreases the concentration of NETs at a target site (e.g. organ or wound) by at least 10%, e.g., by at least 20%, at least 30%, at least 50%, at least 75%, or more as compared to the level of NETs prior to treatment with the anti-NET compound.
In one embodiment, a single administration of an anti-NET compound to a patient decreases the level of an indicator, symptom, or marker of a condition described herein by at least 10%, e.g., by at least 20%, at least 30%, at least 50%, at least 75%, at least 90% more as compared to the level of the indicator, symptom, or marker of the condition prior to treatment with the anti-NET compound.

In certain embodiments the composition comprising at least one anti-NET compound further comprises a pharmaceutically acceptable carrier. Non-limiting examples of antibiotics include, e.g., kanamycin, actinomycin D, doxorubicin, bleomycin, and mithramycin. Antibiotics are well known to those of skill in the art.

In some embodiments, the at least one anti-NET compound or a pharmaceutical composition thereof, is administered with another pharmaceutically active agent, e.g. a pharmaceutically active agent for treating a patient with a wound, fibrosis or diabetes. The anti-NET compound can be administered in combination with other pharmaceuticals and/or other therapeutic methods of treatment concurrently.

In some embodiments, the additional agent administered is an antibiotic, e.g. when the anti-NET compound is used for facilitating wound healing.

In some embodiments, the additional agent administered is an anti-inflammatory agent, anti-A number of anti-inflammatory agents are known in the art, non-limiting examples of which are Alclofenac; Alclometasone Dipropionate; Algestone Acetonide; Alpha Amylase; Amcinafal; Amcinafide; Amfenac Sodium; Amiprilose Hydrochloride; Anakinra; Anirolac; Anitrazafen; Apazone; Balsalazide Disodium; Bendazac; Benoxaprofen; Benzydamine Hydrochloride; Bromelains; Broperamole; Budesonide; Carprofen; Cicloprofen; Cintazone; Claprofen; Clobetasol Propionate; Clobetasone Butyrate; Clopirac; Cloticasone Propionate; Cormethasone Acetate; Cortodoxone; Deflazacort; Desonide; Desoximetasone; Dexamethasone Dipropionate; Diclofenac Potassium; Diclofenac Sodium; Diflorasone Diacetate; Diflumidone Sodium; Diflunisal; Difluprednate; Diftalone, Dimethyl Sulfoxide; Drocinonide; Endrysone; Enlimomab; Enolicam Sodium; Epirizole; Etodolac; Etofenamate; Felbinac; Fenamole; Fenbufen; Fenclodenac; Fenclorac; Fendosal; Fenpipalone; Fentiazac; Flazalone; Fluazacort; Flufenamic Acid; Flumizole; Flunisolide Acetate; Flunixin; Flunixin Meglumine; Fluocortin Butyl; Fluorometholone Acetate; Fluquazone; Flurbiprofen; Fluretofen; Flucicasone Propionate; Furaprofen; Furobufen; Halcinonide; Halobetasol Propionate; Halopredone Acetate; Ibufenac; Ibuprofen; Ibuprofen Aluminum; Ibuprofen Piconol; Ilonidap; Indomethacin; Indomethacin Sodium; Indoprofen;
Indoxole; Intrazole; Isoflupredone Acetate; Isoxepac; Isoxicam; Ketoprofen; Lofemizole Hydrochloride; Lomoxicam; Loteprednol Etabonate; Meclofenamate Sodium; Meclofenamic Acid; Meclorisone Dibutyrate; Meclofenamic Acid; Mesalamine; Meseclazone; Methylprednisolone Suleptanate; Morniflumate; Mefenamic Acid; Meclorisone; Mefenamic Acid; Mesalamine; Meseclazone; Methylprednisolone Suleptanate; Morniflumate; Nabumetone; Naproxen; Naproxen Sodium; Naproxol; Nimazone; Olsalazine Sodium; Orgotein; Orpanoxin; Oxaprozin; Oxyphenbutazone; Paranyline Hydrochloride; Pentosan Polysulfate Sodium; Phenbutazone Sodium Glycerate; Pirfenidone; Paranyline Hydrochloride; Piroxicam; Piroxicam Cinnamate; Piroxicam Olamine; Pirprofen; Prednizate; Prifelone; Prodolic Acid; Proquazone; Proxazole; Proxazole Citrate; Rimexolone; Romazarit; Salcolex; Salnacedin; Salsalate; Salycilates; Sanguinarium Chloride; Seclazone; Sermetacin; Sudoxicam; Sulindac; Suprofen; Talnetacin; Talniflumate; Talyxalate; Tebufelone; Tenidap; Tenidap Sodium; Tenoxicam; Tesicam; Tesimide; Tetrydamine; Tiopinac; Tixocortol Pivalate; Tolmetin; Tolmetin Sodium; Triclonide; Triflumidate; Zidometacin; Glucocorticoids; Zomepirac Sodium.

In some embodiments the additional agent administered is an anti-fibrolytic agent is administered. Additional anti-fibrinolytic agents include, for example, Plasminogen, prekallikrein, kininogens, Factors XII, XHIa, plasminogen proactivator, tissue plasminogen activator [TPA], Streptokinase; Urokinase: Anisoylated Plasminogen-Streptokinase Activator Complex; Pro-Urokinase; (Pro-UK); rTPA (alteplase or activase; r denotes recombinant), rPro-UK; Abbokinase; Eminase; Streptase Anagrelide Hydrochloride; Bivalirudin; Dalteparin Sodium; Danaparoid Sodium; Dazoxiben Hydrochloride; Efegatran Sulfate; Exonaparin Sodium; Ifetroban; Ifetroban Sodium; Tinzaparin Sodium; tenecteplase, retaplase; Trifenenagrel; Warfarin; Dextrans.

In some embodiments, the additional agent administered is agent to treat diabetes. Such agents include those agents known in the art for treatment of diabetes and for having anti-hyperglycemic activities, for example, inhibitors of dipeptidyl peptidase 4 (DPP-4) (e.g., Alogliptin, Linagliptin, Saxagliptin, Sitagliptin, Vildagliptin, and Berberine), biguanides (e.g., Metformin, Buformin and Phenformin), peroxisome proliferator-activated receptor (PPAR) modulators such as thiazolidinediones (TZDs) (e.g., Pioglitazone, Rosiglitazone, and Troglitazone), dual PPAR agonists (e.g., Aleglitazar, Muraglitazar and Tesaglitazar), sulfonylureas (e.g., Acetohexamide, Carbutamide, Chlorpropamide, Gliclazide, Tolbutamide, Tolazamide, Glibenclamide (Glyburide), Glipizide, Gliquidone, Glycropyramide, and Glimipiride), meglitinides ("glinides") (e.g., Nateglinide, Repaglinide and Mitiglinide), glucagon-like peptide-1 (GLP-1) and analogs
(e.g., Exendin-4, Exenatide, Liraglutide, Albiglutide), insulin and insulin analogs (e.g.,
Insulin lispro, Insulin aspart, Insulin glulisine, Insulin glargine, Insulin detemir, Exubera and
NPH insulin), alpha-glucosidase inhibitors (e.g., Acarbose, Miglitol and Voglibose), amylin
analogues (e.g. Pramlintide), Sodium-dependent glucose cotransporter T2 (SGLT T2) inhibitors
(e.g., Dapagliflozin, Remogliflozin and Sergliflozin) and others (e.g. Benfluorex and
Tolrestat).

[00160] The anti-NET compound and the pharmaceutically active agent can be
administered to the subject in the same pharmaceutical composition or in different
pharmaceutical compositions (at the same time or at different times). When administrated at
different times, an anti-NET compound and the pharmaceutically active agent can be
administered within 5 minutes, 10 minutes, 20 minutes, 60 minutes, 2 hours, 3 hours, 4,
hours, 8 hours, 12 hours, 24 hours of administration of the other. When the anti-NET
compound, and the pharmaceutically active agent are administrated in different
pharmaceutical compositions, routes of administration can be different. For example, the
anti-NET compound is administered by any appropriate route known in the art including, but
not limited to oral or parenteral routes, including intravenous, intramuscular, subcutaneous,
transdermal, airway (aerosol), pulmonary, nasal, rectal, and topical (including buccal and
sublingual) administration, and pharmaceutically active agent is administration by a different
route, e.g. a route commonly used in the art for administration of said pharmaceutically active
agent. In a non-limiting example, an anti-NET compound can be administrated orally, while a
pharmaceutically active agent can be administrated subcutaneously.

[00161] Efficacy of treatment or prevention of disease can be assessed, for example by
measuring a marker, indicator, or symptom of the condition, or any other measurable
parameter appropriate. It is well within the ability of one skilled in the art to monitor efficacy
of treatment or prevention by measuring any one of such parameters, or any combination of
parameters.

[00162] A treatment is evident when there is a statistically significant improvement in
one or more parameters of health, or by a failure to worsen or to develop symptoms where
they would otherwise be anticipated. As an example, a favorable change of at least 10% in a
measurable parameter of fibrosis, wound healing, or diabetes, and preferably at least 20%,
30%, 40%, 50%, or more can be indicative of effective treatment. Efficacy for a given anti-
NET compound or formulation of that drug can also be judged using an experimental animal
model for a condition described herein as known in the art. When using an experimental
animal model, efficacy of treatment is evidenced when a statistically significant increase in a
marker is observed.

[00163] The dosage ranges for the administration of an anti-NET compound depend
upon the form of the compound, its potency, and the extent to which symptoms, markers, or
indicators of a condition described herein are desired to be reduced, for example the
percentage reduction desired for collagen deposition, inflammation, scar size. The dosage
should not be so large as to cause adverse side effects, such as hyperviscosity syndromes,
pulmonary edema, congestive heart failure, and the like. Generally, the dosage will vary with
the age, condition, and sex of the patient and can be determined by one of skill in the art. The
dosage can also be adjusted by the individual physician in the event of any complication.

[00164] Patients can be administered a therapeutic amount of an anti-NET compound,
such as 0.5 ng/kg, 1.0 ng/kg, 2.0 ng/kg, 2.5 ng/kg, 5 ng/kg, 10 ng/kg, 15 ng/kg, 20 ng/kg, 25
ng/kg, 30 ng/kg, 40 ng/kg or 50 ng/kg, 0.5 mg/kg, 1.0mg/kg, 2.0 mg/kg, 2.5 mg/kg, 5 mg/kg,
10 mg/kg, 15 mg/kg, 20 mg/kg, 25 mg/kg, 30 mg/kg, 40 mg/kg or 50 mg/kg. The anti-NET
compound can be administered, for example, by intravenous infusion over a period of time,
such as over a 5 minute, 10 minute, 15 minute, 20 minute, or 25 minute period. The
administration is repeated, for example, on a regular basis, such as hourly for 3 hours, 6
hours, 12 hours or longer or such as biweekly (i.e., every two weeks) for one month, two
months, three months, four months or longer. After an initial treatment regimen, the
treatments can be administered on a less frequent basis. For example, after administration
biweekly for three months, administration can be repeated once per month, for six months or
a year or longer. Administration of the anti-NET compound can reduce levels of a marker or
symptom of a condition described herein, e.g., inflammation or collagen deposition by at
least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 40%, at least 50%, at
least 60%, at least 70%, at least 80% or at least 90% or more.

[00165] Before administration of a full dose of the anti-NET compound, patients can
be administered a smaller dose, such as a 5% infusion, and monitored for adverse effects,
such as an allergic reaction.

[00166] In general, the efficacy of a given treatment can be monitored by assessing the
disruption of NETs, as increased NETs have been associated with the conditions described
herein. A reduction in NETs can be determined by tissue analysis and anti-Net
antibodies. However, a treatment is considered "effective treatment," as the term is used
herein, if any one or all of the signs or symptoms of a condition described herein are altered
in a beneficial manner, other clinically accepted symptoms are improved, or even ameliorated, e.g., by at least 10% following treatment with a compound as described herein. Efficacy can also be measured by a failure of an individual to worsen as assessed by hospitalization, or need for medical interventions (i.e., progression of the disease is halted). Another marker of the efficacy of treatment as described herein is survival. Statistical survival rates for specific conditions described herein are well established - when an individual or group of individuals treated according to the methods described herein survives beyond the expected time or at a greater than expected rate, the treatment can be considered effective.

Pharmaceutical Compositions

[00167] For administration to a subject, the compounds can be provided in pharmaceutically acceptable compositions. These pharmaceutically acceptable compositions comprise a therapeutically-effective amount of at least one anti-NET compound described above, formulated together with one or more pharmaceutically acceptable carriers (additives) and/or diluents. As described in detail below, the pharmaceutical compositions described herein can be specially formulated for administration in solid or liquid form, including those adapted for the following: (1) oral administration, for example, drenches (aqueous or non-aqueous solutions or suspensions), lozenges, dragees, capsules, pills, tablets (e.g., those targeted for buccal, sublingual, and systemic absorption), boluses, powders, granules, pastes for application to the tongue; (2) parenteral administration, for example, by subcutaneous, intramuscular, intravenous or epidural injection as, for example, a sterile solution or suspension, or sustained-release formulation; (3) topical application, for example, as a cream, lotion, gel, ointment, or a controlled-release patch or spray applied to the skin; (4) intravaginally or intrarectally, for example, as a pessary, cream, suppository or foam; (5) sublingually; (6) ocularly; (7) transdermally; (8) transmucosally; or (9) nasally. Additionally, compounds can be implanted into a patient or injected using a drug delivery system. Coated delivery devices can also be useful. See, for example, Urquhart, et al., Ann. Rev. Pharmacol. Toxicol. 24: 199-236 (1984); Lewis, ed. "Controlled Release of Pesticides and Pharmaceuticals" (Plenum Press, New York, 1981); U.S. Pat. No. 3,773,919; U.S. Pat. No. 6,747,014; and U.S. Pat. No. 35 3,270,960.

[00168] As used here, the term "pharmaceutically acceptable" refers to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and
animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.

[00169] As used here, the term "pharmaceutically-acceptable carrier" means a pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, manufacturing aid (e.g., lubricant, talc magnesium, calcium or zinc stearate, or steric acid), or solvent encapsulating material, involved in carrying or transporting the subject compound from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials which can serve as pharmaceutically-acceptable carriers include, but are not limited to: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, methylcellulose, ethyl cellulose, microcrystalline cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) lubricating agents, such as magnesium stearate, sodium lauryl sulfate and talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol (PEG); (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) pH buffered solutions; (21) polyesters, polycarbonates and/or polyanhydrides; (22) bulking agents, such as polypeptides and amino acids (23) serum component, such as serum albumin, HDL and LDL; (22) C2-C12 alcohols, such as ethanol; and (23) other non-toxic compatible substances employed in pharmaceutical formulations.

Wetting agents, binding agents, fillers, lubricants, coloring agents, disintegrants, release agents, coating agents, sweetening agents, flavoring agents, perfuming agents, preservative, water, salt solutions, alcohols, antioxidants, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like can also be present in the formulation. The terms such as "excipient", "carrier", "pharmaceutically acceptable carrier" or the like are used interchangeably herein.

[00170] Many organized surfactant structures have been studied and used for the formulation of drugs. These include monolayers, micelles, bilayers and vesicles. Vesicles,

[00171] The compositions described herein can be prepared and formulated as emulsions or microemulsions. Emulsions are typically heterogeneous systems of one liquid dispersed in another in the form of droplets usually exceeding 0.1 µm in diameter and have been described in the art. Microemulsion can be defined as a system of water, oil and amphiphile which is a single optically isotropic and thermodynamically stable liquid solution and can comprise surfactants and cosurfactants. Both of these drug delivery means have been described in the art (see e.g., Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems, Allen, L.V., Popovich NG., and Ansel HC, 2004, Lippincott Williams & Wilkins (8th ed.), New York, NY; Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199; Rosoff, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., Volume 1, p. 245; Block in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 2, p. 199, 245, & 335; Higuchi et al., in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa., 1985, p. 301; Leung and Shah, in: Controlled Release of Drugs:
In one embodiment, the liposome or emulsion formulation comprises a surfactant. Surfactants find wide application in formulations such as emulsions (including microemulsions) and liposomes. The nature of the hydrophilic group (also known as the "head") provides the most useful means for categorizing the different surfactants used in formulations (Rieger, in Pharmaceutical Dosage Forms, Marcel Dekker, Inc., New York, N.Y., 1988, p. 285). Suitable surfactants include fatty acids and/or esters or salts thereof, bile acids and/or salts thereof. In certain embodiments, the surfactant can be anionic, cationic, or nonionic. The use of surfactants in drug products, formulations and in emulsions has been reviewed (Rieger, in Pharmaceutical Dosage Forms, Marcel Dekker, Inc., New York, N.Y., 1988, p. 285).

Oral formulations and their preparation are described in detail in U.S. Patent 6,887,906, U.S. Publication. No. 20030027780, and U.S. Patent No. 6,747,014, each of which is incorporated herein by reference. Compositions and formulations for parenteral, intraparenchymal (into the brain), intrathecal, intraventricular or intrahepatic administration can include sterile aqueous solutions which can also contain buffers, diluents and other suitable additives such as, but not limited to, penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients. Aqueous suspensions can further contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension can also contain stabilizers.

A composition comprising at least one anti-NET compound can be administered directly to the airways of a subject in the form of an aerosol or by nebulization. For use as aerosols, an anti-NET compound in solution or suspension may be packaged in a pressurized aerosol container together with suitable propellants, for example, hydrocarbon propellants like propane, butane, or isobutane with conventional adjuvants. An anti-NET compound can also be administered in a non-pressurized form such as in a nebulizer or atomizer.

An anti-NET compound can also be administered directly to the airways in the form of a dry powder. For use as a dry powder, an anti-NET compound can be administered by use of an inhaler. Exemplary inhalers include metered dose inhalers and dry powdered inhalers.

The compositions can also be delivered by injection, e.g. locally to fibrotic tissue and organs. In certain embodiments, the compositions are delivered using a device, or bandage, used in the process of treatment of a wound.

The compositions described herein can additionally contain other adjunct components conventionally found in pharmaceutical compositions, at their art-established usage levels. Thus, for example, the compositions can contain additional, compatible, pharmaceutically-active materials such as, for example, antipruritics, astringents, local anesthetics or anti-inflammatory agents, or can contain additional materials useful in physically formulating various dosage forms of the compositions described herein, such as dyes, flavoring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers. However, such materials, when added, should not unduly interfere with the biological activities of the components of the compositions described herein. The formulations can be sterilized and, if desired, mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings and/or aromatic substances and the like which do not deleteriously interact with the anti-NET compound(s) of the formulation.

As used herein, the phrase "subject in need of treatment" refers to a subject who is diagnosed with or identified as suffering from, having or at risk for developing the condition to be treated, e.g. fibrosis, diabetes or wounds.

Toxicity and therapeutic efficacy can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50. Compositions that exhibit large therapeutic indices, are preferred. Murine genetics and surgical techniques have generated a number of mouse models for the study of fibrosis and diabetes or mice impaired in the ability to limit the concentration of NETs. Such models can be used for in vivo testing of anti-NET compounds, as well as for determining a therapeutically effective dose. A
suitable mouse model is, for example, the DNase \(^{−}\) mouse described herein or the mouse model of stroke described herein.

**[00182]** The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage can vary within this range depending upon the dosage form employed and the route of administration utilized.

**[00183]** The therapeutically effective dose can be estimated initially from cell culture assays. A dose can be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 (i.e., the concentration of the therapeutic which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Levels in plasma can be measured, for example, by high performance liquid chromatography. The effects of any particular dosage can be monitored by a suitable bioassay.

**[00184]** The amount of an anti-NET compound which can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect. Generally out of one hundred percent, this amount will range from about 0.1% to 99% of compound, preferably from about 5% to about 70%, most preferably from 10% to about 30%.

**[00185]** The dosage can be determined by a physician and adjusted, as necessary, to suit observed effects of the treatment. Generally, the compositions are administered so that the anti-NET compound is given at a dose from 1 µg/kg to 150 mg/kg, 1 µg/kg to 100 mg/kg, 1 µg/kg to 50 mg/kg, 1 µg/kg to 20 mg/kg, 1 µg/kg to 10 mg/kg, ^g/kg to 1mg/kg, 100 µg/kg to 100 mg/kg, 100 µg/kg to 50 mg/kg, 100 µg/kg to 20 mg/kg, 100 µg/kg to 10 mg/kg, 100µg/kg to 1mg/kg, 1 mg/kg to 100 mg/kg, 1 mg/kg to 50 mg/kg, 1 mg/kg to 20 mg/kg, 1 mg/kg to 10 mg/kg, 10 mg/kg to 100 mg/kg, 10 mg/kg to 50 mg/kg, or 10 mg/kg to 20 mg/kg. It is to be understood that ranges given here include all intermediate ranges, for example, the range 1 mg/kg to 10 mg/kg includes 1mg/kg to 2 mg/kg, 1mg/kg to 3 mg/kg, 1mg/kg to 4 mg/kg, 1mg/kg to 5 mg/kg, 1mg/kg to 6 mg/kg, 1mg/kg to 7 mg/kg, 1mg/kg to 8 mg/kg, 1mg/kg to 9 mg/kg, 2mg/kg to 10mg/kg, 3mg/kg to 10mg/kg, 4mg/kg to 10mg/kg, 5mg/kg to 10mg/kg, 6mg/kg to 10mg/kg, 7mg/kg to 10mg/kg, 8mg/kg to 10mg/kg, 9mg/kg to 10mg/kg etc. . It is to be further understood that the ranges intermediate to the given above are also within the scope of the methods and compositions described herein, for example, in
the range 1mg/kg to 10 mg/kg, dose ranges such as 2mg/kg to 8 mg/kg, 3mg/kg to 7 mg/kg, 4mg/kg to 6mg/kg etc.

[00186] With respect to duration and frequency of treatment, it is typical for skilled clinicians to monitor subjects in order to determine when the treatment is providing therapeutic benefit, and to determine whether to increase or decrease dosage, increase or decrease administration frequency, discontinue treatment, resume treatment or make other alteration to treatment regimen. The dosing schedule can vary from once a week to daily depending on a number of clinical factors, such as the subject's sensitivity to the anti-NET compound. The desired dose can be administered at one time or divided into subdoses, e.g., 2-4 subdoses and administered over a period of time, e.g., at appropriate intervals through the day or other appropriate schedule. Such sub-doses can be administered as unit dosage forms. In some embodiments, administration is chronic, e.g., one or more doses daily over a period of weeks or months. Examples of dosing schedules are administration daily, twice daily, three times daily or four or more times daily over a period of 1 week, 2 weeks, 3 weeks, 4 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, or 6 months or more. The desired dose can be administered using continuous infusion or delivery through a controlled release formulation. In that case, the anti-NET compound contained in each sub-dose must be correspondingly smaller in order to achieve the total daily dosage. The dosage unit can also be compounded for delivery over several days, e.g., using a conventional sustained release formulation which provides sustained release of the anti-NET compound over a several day period. Sustained release formulations are well known in the art and are particularly useful for delivery of agents at a particular site, such as could be used with the agents described herein. In this embodiment, the dosage unit contains a corresponding multiple of the daily dose.

[00187] The skilled artisan will appreciate that certain factors can influence the dosage and timing required to effectively treat a subject, including but not limited to the severity of the disease or disorder, previous treatments, the general health and/or age of the subject, and other diseases present. Moreover, treatment of a subject with a therapeutically effective amount of a composition can include a single treatment or a series of treatments. Estimates of effective dosages and in vivo half-lives for the anti-NET compounds described herein can be made using conventional methodologies or on the basis of in vivo testing using an appropriate animal model, as described elsewhere herein.

A method of assessing efficacy of anti-NET treatments
As described herein, the inventors have found that increased levels of NETs are associated with impaired wound healing, diabetes and fibrosis, and have provided methods of treating or preventing these disorders by administering one or more anti-NET compounds. Accordingly, some embodiments are generally related to assays and methods for assessing the efficacy of the administration of one or more anti-NET compounds. In certain embodiments, the assays and methods are directed to determination of the level of NETs in a biological sample of a subject.

The methods and assays described herein include determining the level of NETs in samples obtained from a patient before and after treatment with one or more anti-NET compounds, wherein a reduction in the level of NETs following the treatment with the anti-NET compound is indicative of efficacy.

The sample obtained from a patient can include, but is not limited to, blood or blood products. Blood products in the context of samples obtained from a patient can include, but are not limited to, any component of a patient's blood (e.g. plasma) and/or blood or a component thereof that has been treated or processed (e.g. with an anti-coagulant or preservative).

In certain embodiments, the sample obtained from the patient prior to treatment with one or more anti-NET compounds can be obtained at any time prior to administration of the anti-NET compound, for example, about 1 minute prior to treatment, about 10 minutes prior to treatment, about 1 hour prior to treatment, about 1 day prior to treatment, about 1 week prior to treatment, about 2 weeks prior to treatment, about 1 month prior to treatment, or earlier. In certain embodiments, the sample obtained from the patient after treatment with one or more anti-NET compounds can be obtained at any time after administration of the anti-NET compound, for example, about 10 minutes after treatment, about 1 hour after treatment, about 1 day after treatment, about 1 week after treatment, about 2 weeks after treatment, or later.

In certain embodiments, the level of NETs is determined using labeled DNA detection reagents (i.e. Hoechst 33258 or SytoxGreen), immunodetection of citullinated histones, detection of nucelosomes and/or components thereof (i.e. Cell death detection kit, Roche), or electrophoresis of plasma DNA.

Some embodiments of the present invention may be defined in any of the following numbered paragraphs:
Paragraph 1. A method of treating or preventing organ fibrosis in a subject, the method comprising:
administering to a subject in need of treatment, a therapeutically effective amount of at least one anti-NET compound.

Paragraph 2. The method of paragraph 1, wherein the at least one anti-NET compound is selected from the group consisting of:
DNase; a histone-degrading enzyme; an inhibitor of chromatin decondensation; an antibody against a component of a NET; a protease inhibitor, an elastase inhibitor; and a PAD4 inhibitor.

Paragraph 3. The method of any of paragraphs 1 to 2, wherein the PAD4 inhibitor is selected from the group consisting of:
Cl-amidine and F-amidine.

Paragraph 4. The method of any of paragraphs 1 to 3, wherein said therapeutically effective amount of anti-NET compound is administered prophylactically.

Paragraph 5. The method of any of paragraphs 1 to 4, wherein the subjects age is selected from the group consisting of: over 40 years of age, over 30 years of age, over 50 years of age, over 60 years of age, and over 70 years of age.

Paragraph 6. The method of any of paragraphs 1 to 5, wherein the subject is diagnosed with a disease selected from the group consisting of: heart disease, lung disease, kidney disease, liver disease, and diabetes.

Paragraph 7. The method of any of paragraphs 1 to 6, wherein said therapeutically effective amount of anti-NET compound is given repeatedly.

Paragraph 8. The method of any of paragraphs 1 to 7, wherein the subject is diagnosed as having age-related organ fibrosis.

Paragraph 9. The method of any of paragraphs 1 to 8, wherein the subject is diagnosed with an organ fibrosis selected from the group consisting of: heart fibrosis, lung fibrosis, liver fibrosis, kidney fibrosis, skin fibrosis, soft tissue fibrosis, and intestine fibrosis.

Paragraph 10. The method of any of paragraphs 1 to 9, wherein the administration is local administration to one or more target sites in an organ having fibrosis.

Paragraph 11. The method of any of paragraphs 1 to 10, wherein the subject does not have cystic fibrosis.

Paragraph 12. A method for facilitating wound healing comprising administering a therapeutically effective amount of at least one anti-NET compound.
Paragraph 13. The method of claim 12, wherein the anti-NET compound is selected from the group consisting of:
DNase; a histone-degrading enzyme; an inhibitor of chromatin decondensation; an antibody against a component of a NET; a protease inhibitor, an elastase inhibitor; and a PAD4 inhibitor.

Paragraph 14. The method of any of paragraphs 12 to 13, wherein a DNAse and an additional anti-NET compound selected from the group consisting of; a histone-degrading enzyme; an inhibitor of chromatin decondensation; a NET release inhibitor; an antibody against a component of a NET; a protease inhibitor, an elastase inhibitor; and a PAD4 inhibitor, are administered.

Paragraph 15. The method of any of paragraphs 12 to 13, wherein the anti-NET compound is not a DNase.

Paragraph 16. The method of any of paragraphs 12 to 15, wherein the PAD4 inhibitor is selected from the group consisting of:
Cl-amidine and F-amidine.

Paragraph 17. The method of any of paragraphs 12 to 16, wherein said therapeutically effective amount of anti-NET compound is administered prophylactically.

Paragraph 18. The method of any of paragraphs 12 to 17, wherein said therapeutically effective amount of anti-NET compound is given repeatedly.

Paragraph 19. The method of any of paragraphs 12 to 18, wherein the subject is diagnosed as having diabetes.

Paragraph 20. A method for treating NET associated inflammation and complications in diabetes comprising administering a therapeutically effective amount of at least one anti-NET compound.

Paragraph 21. The method of claim 20, wherein the anti-NET compound is selected from the group consisting of:
DNase; a histone-degrading enzyme; an inhibitor of chromatin decondensation; a NET release inhibitor; an antibody against a component of a NET; a protease inhibitor, an elastase inhibitor; and a PAD4 inhibitor.

Paragraph 22. The method of any of paragraphs 20 to 21, wherein the anti-NET compound is not a DNase.

Paragraph 23. The method of any of paragraphs 20 to 22, wherein the anti-NET compound is not an elastase inhibitor.
Paragraph 24. The method any of paragraphs 20 to 23, wherein the PAD4 inhibitor is
selected from the group consisting of:
Cl-amidine and F-amidine.
Paragraph 25. The method of any of paragraphs 20 to 24, wherein said therapeutically
effective amount of anti-NET compound is administered prophylactically.
Paragraph 26. The method of any of paragraphs 20 to 25, wherein said therapeutically
effective amount of anti-NET compound is given repeatedly.
Paragraph 27. The method of any of paragraphs 20 to 26, wherein the subject is diagnosed as
having diabetes type 1.
Paragraph 28. The method of any of paragraphs 20 to 27, wherein the subject is diagnosed as
having diabetes type II.
Paragraph 29. The method of any of paragraphs 20 to 28, wherein inflammation is reduced
by at least 10%, at least 20%, at least 30%, or at least 50% as compared to inflammation prior
to treatment.

EXAMPLES

EXAMPLE 1: NETS impair wound healing, especially in Diabetes

METHODS

Animals. All animal procedures were reviewed and approved by the
Institutional Animal Care and Use Committee of Boston Children's Hospital. CD18−/− mice
and PAD4−−/− mice were on a C57BL/6J background and were routinely crossed to WT mice
from the Jackson Laboratory (Bar Harbor, ME). Age- and gender-matched control mice
included the WT littermates of the two strains and C57BL/6J purchased from the Jackson
Laboratory. Nine-week old male diabetic db/db mice and the normoglycemic control m+/db
mice were purchased from Jackson Laboratory. All mice were fed standard lab diet and
maintained under standard laboratory conditions free of specific pathogens. Sample size was
chosen based on previous experience with the animal strains and animal models. Genotypes
of animals were open to investigators.

Human blood cell samples. The study was approved by the Institutional
Review Board of Boston Children's Hospital and Joslin Diabetes Center, and conformed to
the principles outlined in the Declaration of Helsinki. Blood samples were obtained after
written informed consent was obtained. Diabetic patients were recruited only if they were
below 70 years old, not on steroid or other immunosuppressive medications, not presenting
any signs of active infection (fever, high leukocyte count and diagnosis of infection), no
diagnosis of cancer in the past 5 years and no overt heart failure.

**Induction of diabetic murine model.** Mice were induced to be diabetic using
multiple low dose injections of streptozotocin (STZ). Six to 8-week old male C57BL/6 or
*PAD4*−/− mice were randomized into treatment groups of either vehicle or STZ according
to their blood glucose levels and body weight at baseline. Mice were fasted for 5 hours and then
injected with vehicle or STZ (i.p., 50 mg/kg per day, pH 4, dissolved in 0.1 M sodium citrate
buffer) for 5 consecutive days. Fed blood glucose level was measured starting 1 week
afterwards. Mice with fed blood glucose level above 300 mg/dL were considered diabetic and
used for further experiments. Pancreatic islets were stained for insulin using a rabbit
polyclonal anti-insulin antibody (1:500, Cell Signaling, Cat. no. 4590).

**Measurement of basal H3Cit on mouse cytopsins.** Murine whole blood was
collected via the retro-orbital venous plexus. Red blood cells were lysed using ACK lysing
buffer. After centrifugation, cells were resuspended in 7.5% BSA/PBS and spun at 1600 rpm
for 4 minutes onto slides and instantly fixed with 4% PFA at 4°C overnight and then stained
using rabbit polyclonal anti-H3Cit (1:1,000, abeam, Cat. no. ab5103) and rat monoclonal
anti-mouse Ly6G (1:500, BD Pharmingen, Cat. no. 551459). H3Cit+ neutrophils were
determined by thresholding analysis using ImageJ software (NIH).

**Mouse neutrophil isolation and NETosis assay.** Peripheral blood neutrophils
were isolated with Percoll (GE Healthcare) gradients as described. Purity of cells was >90%
as determined by Wright-Giemsa staining. Neutrophils were resuspended in HBSS (with
calcium, magnesium and 5.5 mM glucose) for experiments involving high glucose; otherwise
they were resuspended in HEPES-buffered RPMI medium. Neutrophils were plated at 50,000
cells/well in 96-well glass-bottomed plates and stimulated with *Klebsiella pneumoniae* LPS
(Sigma) at indicated concentrations for 2.5 hours. For high glucose experiments, neutrophils
were isolated from normoglycemic mice and pre-incubated for 1 h in media with normal (5.5
mM) or high (22 mM) glucose concentration. Twenty-two mM corresponds to 396 mg/dL,
which is similar to the fed blood glucose level in STZ-induced mice 8 weeks post-induction
(376.3 ± 26.9 mg/dL). Mannitol (16.5 mM in medium with 5.5 mM glucose) was employed
as an osmotic control. LPS (in respective medium) was added and neutrophils were further
incubated for 2.5 h. Cells were then fixed in 2% PFA, permeabilized, blocked, stained with
anti-H3Cit (1:1,000, abeam, Cat. no. ab5103), Alexa Fluor 488-conjugated anti-rabbit
secondary antibody (1:1,500, Invitrogen) and Hoechst 33342 (1:10,000, Invitrogen).
Percentages of H3Cit\textsuperscript{hi} cells and NETs were determined from 5-6 non-overlapping fields per well and the average was taken from duplicates or triplicates for each condition in every experiment. Exposure time for H3Cit and DNA were identical for all treatments within the same experiment. Spread NETs were counted in a single channel for DNA. Images of this channel were exported in black-and-white for better contrast for quantification.

\textbf{[00201]} \textit{Human neutrophil isolation and NETosis assay.} Blood was drawn from healthy subjects or diabetic patients into EDTA-coated tubes. Neutrophils were isolated using Histopaque\textsuperscript{®}-1 119 (Sigma) and Percoll Plus\textsuperscript{®} (GE Healthcare) gradients as described\textsuperscript{19}, a method that cause minimal activation of neutrophils during isolation. Purity of cells was >95\% as determined by Wright-Giemsa staining. For experiments involving high glucose, neutrophils were resuspended in glucose-free HEPES-buffered RPMI supplemented with glucose at 5.5 mM (normal), 22 mM (high) or 5.5 mM plus 16.5 mM mannitol (osmotic control) and 2\% heat-inactivated fetal bovine serum. Neutrophils were plated at 10,000 cells/well in 96-well Cellbind\textsuperscript{®} plates (Corning). After incubation in respective media for 1 h, cells were stimulated with ionomycin (4 \mu M) or PMA (100 nM) for 2.5 hours. For experiments that did not involve high glucose, cells were resuspended in HEPES-buffered RPMI medium (11 mM glucose) supplemented with 2\% heat-inactivated fetal bovine serum, plated at 10,000 cells/well and incubated with ionomycin (4 \mu M) for 2.5 h. Cells were then instantly fixed in 2\% PFA with Hoechst 33342 (1:10,000) for NET quantification. Percentage of NETs was determined from 6 non-overlapping fields per well and the average was taken from triplicates for each condition in every experiment. Analysis was performed by an experimenter blinded to treatment conditions.

\textbf{[00202]} \textit{Wounding and macroscopic healing assessment.} Full-thickness excisional wounds were made on the dorsal skin under aseptic conditions as described\textsuperscript{22}. Mice were anesthetized with ketamine and xylazine (100 mg/kg and 10 mg/kg, respectively, i.p.). Hair was removed and the skin was cleaned with 70\% ethanol and betadine. A fold of the dorsal skin was then picked up along the midline, placed over dental wax and punched through with a 4-mm disposable sterile biopsy punch (Miltex) such that 2 wounds were generated in one punch. The procedure was repeated, thus 4 wounds were made per mouse. The mice were housed individually after wounding. In experiments involving diabetic mice, all mice were provided ad libitum with antibiotics (2.5\% Sulfatrim) in drinking water. Wounds were digitally photographed using a Sony Camcorder and total wound areas were calculated using
ImageJ software. Wound area was expressed as a percentage compared to the area on day 0 when the wounds were made.

[00203] **Western blot analysis.** Levels of H3Cit and Ly6G of mouse wounds and PAD4 expression in human neutrophils were quantified by Western blot. After collection of mouse wounds or isolation of human neutrophils, the samples were snap frozen and homogenized in RIPA buffer supplemented with protease inhibitor cocktails (Sigma) on ice. After centrifugation at 20,000 g for 20 min at 4°C, the protein content of the supernatant was determined by bicinchoninic acid protein assay and an equal amount of protein per sample was resolved on gradient gels (4-20%, Lonza) and electroblotted on PVDF membranes, which were then incubated with primary antibodies (rabbit polyclonal anti-H3Cit, 1:1,000, abeam, Cat. no. ab5103; rabbit polyclonal anti-H3, 1:6,000, abeam, Cat. no. abl791; rat monoclonal anti-mouse Ly6G, 1:500, BD Pharmingen, Cat. no. 551459; mouse monoclonal anti-human PALM, 1:2,000, abeam, Cat. no. ab128086) at 4°C overnight and subsequently with appropriate HRP-conjugated secondary antibodies for 2 h at room temperature. The blots were developed with enhanced chemiluminescence substrate. Equal loading was confirmed by probing for GAPDH (1:40,000, Ambion; Cat. no. AM4300). Blots were quantified using ImageJ software.

[00204] **Immunofluorescence widefield and confocal microscopy.** Localization of H3Cit and neutrophils in the wounds were examined by immunofluorescence microscopy. Wounds were dissected, cut in half and instantly embedded in OCT. The tissue was cryosectioned into 10 µm and 20 µm sections for wide-field and confocal immunofluorescence microscopy, respectively. The sections were post-fixed in zinc fixative (100 mM Tris-HCl, 37 mM zinc chloride, 23 mM zinc acetate, 3.2 mM calcium acetate), permeabilized and incubated with primary antibodies against H3Cit (1:1,000, abeam, Cat. no. ab5103) and Ly6G (1:500, BD Pharmingen, Cat. no. 551459) at 4°C overnight and then Alexa Fluor-conjugated secondary antibodies (1:1,500, Invitrogen) for 2 hours at room temperature. Hoechst 33342 (1:10,000) was used to stain for DNA. Images were acquired with Zeiss Axiovision software using an Axiovert 200 wide-field fluorescence microscope (Zeiss) coupled to an Axiocam MRm monochromatic CCD camera (Zeiss) or with Olympus Fluoview software using the Olympus IX 81 confocal microscope.

[00205] **Histological examination.** Neutrophil recruitment and re-epithelialization were examined in H&E-stained sections. Wounds were cut in half, fixed overnight in zinc fixative and embedded in paraffin. The tissue was sectioned at 10 µm and stained with H&E. Images
were acquired with the Zeiss Axiovision software using an Axioplan light microscope coupled to a color Zeiss HRc camera.

**Neutrophil depletion.** Neutrophils of 10-week old WT mice were depleted one day before wounding by i.v. injection of a specific anti-neutrophil antibody (ultra-low endotoxin and azide free rat anti-Ly6G, 1A8 clone, Biolegend, Cat. no. 127632) at a dose of 5 μg/g mouse. Control mice were injected with rat IgG. The mice were re-dosed at 2.5 μg/g mouse 2 days after the first injection. Levels of circulating neutrophils were evaluated by flow cytometry (BD FACSCanto II) using a FITC-conjugated rat monoclonal anti-mouse neutrophil antibody (1:300, anti-7/4, abeam, Cat. no. ab53453) and analyzed using FlowJo software. About 80% of circulating neutrophils were depleted throughout the 3-day wound healing period.

**DNase 1 treatment.** Normoglycemic and diabetic WT mice, randomized by blood glucose levels before assigning to treatments, were injected with 10 μg i.v. and 50 μg i.p. DNase 1 (dornase alfa, Genentech) 30 min before wounding and then 50 μg i.p. every 12 hours until wound collection on day 3. Control mice were injected with vehicle (8.77 mg/mL sodium chloride and 0.15 mg/mL calcium chloride).

**Statistical analysis** Data are presented as mean ± s.e.m. of at least two independent experiments, and were analyzed using Mann-Whitney test, two-tailed Student's t-test (unpaired), Kruskal-Willis test followed by Dunn's post test, or repeated measures ANOVA with Bonferroni's post test, where appropriate. Percentage of mice with total wound closure and rate of diabetes induction between WT and **PAD4**−− were analyzed with two-tailed Fisher's exact test of contingency tables. Percentage of mice with open wounds was analyzed with the log-rank test after constructing the Kaplan-Meier curves. All analyses were performed using GraphPad Prism software (Version 5.0). Results were considered significant when P<0.05.

**NETs** were originally recognized as a host defense mechanism in which neutrophils release their nuclear and granular contents to contain and kill pathogens. Bacterial endotoxins, such as lipopolysaccharides (LPS), stimulate the release of NETs that form extensive webs of DNA coated with cytotoxic histones and microbicidal proteases. A prerequisite for NETosis is modification of arginine residues of histones to citrulline by PAD4, which changes the charge of the histones, leading to massive chromatin decondensation. Recently it became evident that NETs also form during sterile...
inflammation. NETs are a key scaffold in pathologic thrombi and fuel cardiovascular, inflammatory and thrombotic diseases in mice and humans.

Under diabetic conditions, neutrophils produce more superoxide and cytokines. Tumor necrosis factor-a, which primes neutrophils for NETosis, is increased in diabetic patients. The diabetic microenvironment is thus pro-NETotic. To test whether diabetes predisposes neutrophils to NETosis, we isolated neutrophils from the fresh whole blood obtained from both type 1 and type 2 diabetic patients whose glycated hemoglobin (HbAlc) was >6.5%, indicating mild prolonged hyperglycemia (Fig. 1a). Neutrophils from these patients were indeed more susceptible to NETosis when stimulated with the calcium ionophore, ionomycin (Fig. 1b). PAD4 is a calcium-dependent enzyme that is key in mediating NETosis. Western blotting revealed a 4-fold upregulation of PAD4 protein expression in the neutrophils from diabetic patients (Fig. 1c), which may explain their higher susceptibility to NET formation. Our present findings are complemented by a recent report showing that circulating NET-related biomarkers, nucleosomes, cell-free double-strand DNA and neutrophil elastase, are increased in type 2 diabetic patients' serum, and that nucleosomes positively correlate with the patients' HbAlc levels.

Because hyperglycemia is common to both type 1 and type 2 diabetes, as indicated by the significantly higher HbAlc in the diabetic cohort compared to the healthy controls (Fig. 1a, [Table 1]), we hypothesized that high glucose may contribute to neutrophil priming. We therefore isolated neutrophils from healthy donors and pre-incubated them in media with normal or high glucose concentrations prior to stimulation with ionomycin or phorbol 12-myristate 13-acetate (PMA) which triggers production of reactive oxygen species (ROS). Both ionomycin and PMA stimulated more of the high glucose-exposed neutrophils to produce NETs compared to pre-incubation with normal glucose or equal concentrations of the non-metabolizable sugar alcohol, mannitol (Fig. 1d, and data not shown). Thus, the increased susceptibility of diabetic neutrophils to NETosis is at least in part due to elevations in blood glucose. Our observations differ from earlier reports which suggested that high glucose/diabetes does not affect or impairs NETosis. This difference is likely due to the pre-activation of human neutrophils during isolation with dextran sedimentation, a method that can induce ROS production and NET formation prior to culture, which could result in the loss of the primed neutrophil population during the preparatory process in the previous studies. Using Histopaque/Percoll gradients for human neutrophil isolation, we found a clear priming effect by diabetes or high glucose on NETosis.
### Table 1 Parameters of healthy subjects and diabetic patients

<table>
<thead>
<tr>
<th></th>
<th>Healthy Subjects</th>
<th>Diabetic Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age (years)</strong></td>
<td>36 ± 6</td>
<td>40 ± 6</td>
</tr>
<tr>
<td><strong>Leukocyte count (K/μL)</strong></td>
<td>6.00 ± 0.70</td>
<td>6.58 ± 1.07</td>
</tr>
<tr>
<td><strong>Platelet count (K/μL)</strong></td>
<td>299.20 ± 20.00</td>
<td>276.20 ± 12.20</td>
</tr>
<tr>
<td><strong>HbAlc (%)</strong></td>
<td>5.62 ± 0.08</td>
<td>8.35 ± 0.61 **</td>
</tr>
<tr>
<td><strong>Glucose (mg/dL)</strong></td>
<td>88.50 ± 3.13</td>
<td>134.20 ± 21.67 (a)</td>
</tr>
<tr>
<td><strong>Cholesterol (mg/dL)</strong></td>
<td>178.30 ± 16.28</td>
<td>179.50 ± 16.07</td>
</tr>
<tr>
<td><strong>Triglycerides (mg/dL)</strong></td>
<td>102.30 ± 26.24</td>
<td>259.20 ± 97.35</td>
</tr>
<tr>
<td><strong>HDL (mg/dL)</strong></td>
<td>72.50 ± 14.31</td>
<td>54.67 ± 11.79</td>
</tr>
<tr>
<td><strong>LDL (mg/dL)</strong></td>
<td>86.17 ± 9.01</td>
<td>97.83 ± 16.00</td>
</tr>
</tbody>
</table>

**P<0.01, (a) P = 0.0542 versus healthy subjects**

We then examined the susceptibility to NETosis in diabetic mouse models, which are amenable to experimentation needed to study the role of PAD4 and impact of NETs on diabetic wound healing. Immunostaining of fresh blood cells from streptozotocin (STZ)-induced diabetic mice (a model of type 1 diabetes) (data not shown) revealed a 4-fold increase in neutrophils positive for citrullinated histone H3 (H3Cit), a biomarker of NETosis, compared to normoglycemic mice (data not shown). About 4.5 fold more isolated neutrophils from diabetic mice were H3Cit\textsuperscript{high} (Fig. le) and 2% produced NETs after incubation in vitro without stimulation, while <0.2% NETs were seen in the normoglycemic controls (Fig. If). LPS further stimulated more neutrophils from the STZ-induced diabetic mice to be H3Cit\textsuperscript{high} (Fig. le, Fig. lg) and form NETs (Fig. If, Fig. lg) compared to vehicle-treated normoglycemic mice. Thus, similar to humans, diabetes has inflammatory or metabolic components that predispose mouse neutrophils to NETosis. Although there is no specific anti-mouse PALM antibody to evaluate whether PAD4 protein expression is increased by diabetes, neutrophil priming could be also attributable to an increased PALM activity as indicated by elevated histone H3 citrullination\textsuperscript{4} (Fig. le, data not shown). Similar NETosis assays were performed with neutrophils from genetically modified db/db mice (data not shown), a type 2 diabetic model. These neutrophils were also predisposed to hypercitrullinate histone H3 and form NETs (Fig. lh, Fig. li) when compared to the
neutrophils from normoglycemic control m+/db mice, indicating enhanced NETosis is a common phenomenon in murine diabetes regardless of the type or etiology as we observed in the human condition. LPS again stimulated more of the high glucose-exposed neutrophils from normoglycemic WT mice to histone hypercitrullination (Fig. 1j) and NET production (Fig. 1k), indicating a possible priming role of high glucose. Thus the mouse models of diabetes represent well the human condition in respect to susceptibility to NETosis and induction of PAD4 activity.

Depletion of neutrophils in mice was previously shown to accelerate re-epithelialization of uninfected diabetic wounds. Because NETs can be injurious to tissues, we asked whether NETs form in wounds and impact healing. We examined excisional wounds from normoglycemic WT mice. H&E staining confirmed that recruitment of leukocytes, mainly neutrophils, overlaps with the keratinocyte proliferation stage that leads to re-epithelialization (data not shown). Therefore, neutrophils or NETs could interfere with healing. Analysis of wound proteins by Western blotting showed a progressively increasing level of H3Cit that peaked from 3 to 7 days after wounding (Fig. 2a). Immunofluorescence images of 3-day wounds showed that hypercitrullinated neutrophils were present in the wound bed immediately beneath the scab (data not shown). Confocal microscopy substantiated the presence of NETs in skin wounds. Externalized DNA colocalized with H3Cit in areas associated with intense staining of the neutrophil membrane marker, Ly6G (data not shown). Of note, H3Cit and neutrophils were absent in the surface layers of unwounded skin (data not shown). Skin expresses PAD isoforms which could citrullinate extracellular proteins in the scab. To verify the cellular source of H3Cit, we subjected CD18 (132 integrin)-deficient (CD18<−> mice, which are defective in leukocyte recruitment, to wounding. In these mice, both H3Cit and Ly6G were undetectable by Western blotting in 3-day wounds (Fig. 2b, left panels), a time when H3Cit was maximal in the WT wounds (Fig. 2a), indicating that H3Cit is of leukocyte origin. H&E staining and immunofluorescence microscopy showed that the few CD18<−> neutrophils present in these wounds were H3Cit+ and produced NETs (data not shown). Indeed, CD75<−> neutrophils produced NETs efficiently in vitro (data not shown), showing that 132 integrins were not required for NETosis. Wounds from WT mice with depleted neutrophils also showed markedly reduced H3Cit (Fig. 2b, right panels). Thus, our data indicate that neutrophils are the source of the H3Cit present in the wounds.
To establish the role of NETs in wound healing, we compared wounds of WT to PAD4−/− mice. Prominent extracellular DNA structures observed by H&E were absent in PAD4−/− scabs (data not shown), as were the H3Cit and extracellular chromatin patterns seen in WT mice by confocal microscopy (data not shown). In contrast to the robust H3Cit signals in WT wounds, no H3Cit was detected in wounds from PAD4−/− mice despite normal neutrophil recruitment (Fig. 3a and data not shown). Unlike neutrophil recruitment-defective P-/E-selectin double mutants that have opportunistic infections24 and impaired wound healing22, wounds in PAD4−/− mice did not show overt signs of infection (Fig. 3b) and healed faster than WT (Fig. 3b, Fig. 3c). This is likely because other neutrophil functions such as phagocytosis13, degranulation and ROS production (our unpublished observations) are intact in PAD4−/− neutrophils so that these neutrophils are fully capable of performing other host defense mechanisms. About 80% of PAD4−/− mice had all wounds healed on day 14 compared to only 25% of WT controls (Fig. 3d). The beneficial effect of PAD4 deficiency on wound healing was observed very early after injury (Fig. 3c), indicating that NETs might impair the onset of initial healing processes such as keratinocyte migration. In line with this hypothesis, re-epithelialization progressed 3-fold faster in PAD4−/− mice compared to WT (Fig. 3e, and data not shown). Immunofluorescence staining of Ki67 (a proliferation marker) and TUNEL (an indicator of apoptosis) was not different between 3-day wounds from WT and PAD4−/− mice (data not shown). It is thus likely that migration per se is affected, perhaps due to a modification of matrix proteins induced by NETs. Although WT and PAD4−/− neutrophils also express PAD2 and PAD311, our data demonstrate that PAD4, the only nuclear PAD, is essential for the histone H3 citrullination and NETosis in skin wounds. Coudane et al.25 reported that PAD4 is the main PAD isoform detected in scabs of wounds from WT mice, and that PAD2 is unnecessary for citrullination of scab proteins as observed in PAD2-deficient mice, further strengthening the unique demination role of PAD4 in the wounds.

We next examined whether NETs interfere with diabetic wound healing. Type 1 diabetes was induced in WT and PAD4−/− mice by STZ and 8 weeks later these mice were subjected to wounding. Changes in body weight, fed blood glucose and diabetes induction rate were similar between the two genotypes (Fig. 9d-f). As expected, diabetic WT mice healed more slowly than normoglycemic controls (Fig. 4a). All normoglycemic WT mice healed by day 16, while -20% of diabetic mice still had open wounds on day 19 (Fig. 4d). Diabetic PAD4−/− mice healed >35% faster than diabetic WT mice on day 7 (Fig. 4b) and had
all wounds closed by day 15 (Fig. 4e). Notably, diabetes did not impair wound healing in PAD4−/− mice (Fig. 4c,f), which underscores NETs as the major determinant delaying healing in the diabetic mice. Higher H3Cit levels were detected in wounds of STZ-induced diabetic mice compared to the normoglycemic WT mice 1 day post wounding (Fig. 4g). The enhanced NETosis in vivo recapitulates our in vitro observations (Fig. 1e-g), further supporting the role of NETs in the delay in diabetic wound repair. Antibiotics, provided to mimic the medical regimen of diabetic patients with chronic wounds, did not abolish the beneficial effect of PAD4 deficiency ([Supplementary Fig. 10]).

Enhanced wound healing in PAD4−/− mice suggests that NETs may be a redundant host defense mechanism that compromises wound repair. NETs and histones directly induce epithelial and endothelial cell death21, and cause cytotoxicity in vitro and in vivo via calcium influx26. High neutrophil elastase concentration, a component of NETs12, can cause degradation of the wound matrix and delay healing27. Such a cytotoxic environment produced by NETs may explain the slower keratinocyte repopulation in the wound beds of WT mice. Because PAD4 is not expressed in the skin23, its negative effect on wound healing is most likely due to infiltrating neutrophils. In fact, using NETs to defend against microbes may not be very effective during wound healing as Staphylococcus species, which are very abundant in diabetic wounds28, degrade NETs to escape trapping29, and the NET degradation products can affect the proper healing process30,31. Thus, the non-selective cytotoxicity of NETs and/or their degradation products resulting from bacterial infection may profoundly delay wound healing.

Farrera and Fadeel reported that pre-digestion of NETs with DNase 1 accelerated their clearance by macrophages in vitro32. Facilitated clearance of NETs in wounds may reduce their toxicity and diminish wound matrix degradation that is essential for the directional migration of keratinocytes33. We thus tested whether systemic DNase 1 treatment could accelerate wound healing in diabetic mice that were maintained on antibiotics. Without DNase 1 treatment, diabetic PAD4−/− mice healed better in terms of both a greater reduction in wound area (Fig. 4h, upper panel) and more re-epithelialization (Fig. 4h, lower panel) compared to the diabetic WT mice as examined on day 3 post wounding. Administration of DNase 1 promoted wound area reduction by >20% and enhanced re-epithelialization by >75% in diabetic WT mice, an extent similar to that of DNase 1-treated normoglycemic WT mice (Fig. 4h). Interestingly, DNase 1 treatment did not provide further benefits in healing the wounds of diabetic PAD4−/− mice (Fig. 4h). These data indicate that NETs are the major
source of extracellular DNA that hinders wound healing. Such beneficial effects of DNase 1 were not confined to diabetic wounds. Three days post wounding, wound areas in normoglycemic mice treated with DNase 1 were smaller than in those treated with vehicle (Fig. 4i, upper panel). Re-epithelialization was also enhanced by -54% in the DNase 1-treated group (Fig. 4i, lower panel), while neutrophil recruitment was not affected (data not shown). Our current findings corroborate positive results from pilot clinical trials with activated protein C (APC), which cleaves and reduces the cytotoxicity of histones and facilitates healing of chronic wounds and diabetic ulcers. Topical treatment with an ointment containing fibrinolysin and DNase (Elase) is used clinically for wound debridement. In addition to removing necrotic tissue, our findings suggest that the DNase component may also cleave NETs to reduce cytotoxicity and enhance wound recovery.

In summary, our data demonstrate that diabetes activates neutrophils to overproduce PAD4 and NETs and identify NETs as a key factor delaying wound healing. PAD4 inhibition and cleavage of NETs by DNase 1 could be novel therapeutic approaches to wound resolution, not only in diabetes, but also to wounds resulting from aseptic procedures such as surgeries of normoglycemic patients. We further validate the importance of PAD4 in human disease, and report the upregulation of PAD4 in diabetic patients, thus providing new rationale to develop specific PAD4 inhibitors. Because PAD4 and NET formation contribute to inflammatory and thrombotic diseases that are prominent in diabetics, anti-NET therapy could have additional benefits. The increased NETosis in diabetes suggests that NETs may fuel these disorders and inhibiting NETosis or cleavage of NETs may lessen them.

Example 1 References
18. Rebecchi, I.M., Ferreira Novo, N., Julian, Y. & Campa, A. Oxidative metabolism and release of myeloperoxidase from polymorphonuclear leukocytes obtained from


[00221] EXAMPLE 2: PAD4 promotes fibrosis.

[00222] METHODS

[00223] Animals. Twenty-four to 27-month-old C57BL/6 mice for in vitro NETosis studies were obtained from the Aged Rodent Colony of the National Institute on Aging of the National Institutes of Health, maintained at Charles River Laboratories. Young mice (8-16 weeks old) for these experiments were obtained from the same colony.

[00224] PAD4-/- and corresponding wild-type (WT) mice were on a C57BL/6J background. Retired breeders had been kept on LabDiet PicoLab Mouse Diet 20, which is fortified with a higher fat content for growth and reproduction (21.635% calories provided by fat), from 6-10 weeks of age until the time of sacrifice. Non-breeders and all young mice
were kept on a standard laboratory diet (LabDiet Prolab IsoPro RMH 3000, 14.276% calories provided by fat) throughout their life. Young animals were 6-8 weeks, retired breeders were 12-17 months old and old mice that had been kept on standard lab diet were 14-18 months old. Old mice for the diastolic measurements were 18 months old for the PAD4+/− mice and between 15 and 20 months old for the old WT mice, while young mice in this experiment were 8 weeks old.

All groups were age and sex matched, and were fed ad libitum with free access to water. All experimental procedures were reviewed and approved by the Institutional Animal Care and Use Committee of Boston Children's Hospital (protocol no. 14-03-263 1R).

Analysis of peripheral blood and cytospin. Blood was collected from anesthetized mice via the retroorbital sinus into EDTA-coated capillary tubes and was analyzed by a Hemavet 950FS (Drew Scientific) for complete blood counts.

Twenty-five microliters of whole blood was incubated in ACK (ammonium chloride potassium) lysis buffer for 10 min on ice, then cytocentrifuged using a Statspin Cytofuge 2. Samples were immediately fixed in 4% paraformaldehyde for 2 h at room temperature and then immunostained for H3Cit and Ly6G as previously described (16). Images were acquired of cells from 10-15 fields of view at 200x magnification using a Zeiss Axiovert inverted epifluorescence microscope and Zeiss Axiovision software. Thresholding analysis was performed using ImageJ software to calculate the population of H3Cit-positive neutrophils in each sample.

Peripheral blood neutrophil isolation and NET induction. Peripheral blood neutrophils were isolated as described (16) and stimulated with calcium ionophore (4 µM) or PMA (100 nM) for 3.5 h. Cells were fixed with 2% (vol/vol) paraformaldehyde, and DNA was stained with Hoechst 33342 (Invitrogen) for visualization of NETs using an epifluorescent Axiovert microscope (Zeiss). NETs were counted from five distinct fields of view in triplicate wells and expressed as percentage of NET-forming cells per total number of cells in the field.

Plasma collection. Blood was collected from the retroorbital plexus of anesthetized mice (using 3.5 % isoflurane) into sodium citrate anticoagulant (10% vol/vol). Whole blood was centrifuged at 6000 rpm for 5 min, plasma was collected and again centrifuged at 13200 rpm for 5 min to remove any remaining cellular components. Plasma samples were immediately stored at -80°C until analysis.
Echocardiography. Cardiac function and heart dimensions were measured as described. The M-mode was used to evaluate left ventricular (LV) internal dimension (LVID), LV interventricular septum (LVIS), and LV posterior wall thickness (LVPW) at end diastole and end systole. Echocardiograms were stored digitally and ejection fraction (LVEF; percentage) was calculated using Vevostrain software (VisualSonics). Flow pattern across the mitral valve was measured in the 4-chamber view using the Pulsed Wave (PW) Doppler mode to determine evidence of impaired ventricular relaxation. Ventricular filling pattern is expressed as the ratio between the E and the A wave (E/A).

Blood pressure measurements. Systolic blood pressure was measured using a IITC 12M22931 non-invasive blood pressure system (IITC Life Science). Mice were trained twice several days before the measurements to accustom them to measurement conditions. For measurements, the mice were placed into restrainers and allowed to settle down for 10 min. Systolic blood pressure was determined by the tail cuff in a chamber at 34°C. Blood pressure was measured 5 times, and the mean of the obtained values is presented (Table 2).

Table 2

<table>
<thead>
<tr>
<th>Measure</th>
<th>WT</th>
<th>PAD4&lt;sup&gt;−/−&lt;/sup&gt;</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total leukocytes (x10&lt;sup&gt;3&lt;/sup&gt;/μl)</td>
<td>7.90 ± 1.033, n=9</td>
<td>9.06 ± 1.123, n=8</td>
<td>0.4174</td>
</tr>
<tr>
<td>Neutrophils (x10&lt;sup&gt;3&lt;/sup&gt;/μl)</td>
<td>1.76 ± 0.276, n=9</td>
<td>2.28 ± 0.373, n=8</td>
<td>0.1662</td>
</tr>
<tr>
<td>Platelets (x10&lt;sup&gt;6&lt;/sup&gt;/μl)</td>
<td>106 ± 43.67, n=9</td>
<td>1002 ± 38.42, n=8</td>
<td>0.5240</td>
</tr>
<tr>
<td>Weights (g)</td>
<td>39.70 ± 1.283, n=10</td>
<td>36.43 ± 1.525, n=7</td>
<td>0.0951</td>
</tr>
<tr>
<td>Blood pressure (mm Hg)</td>
<td>93.38 ± 1.590, n=9</td>
<td>95.48 ± 2.953, n=10</td>
<td>0.6464</td>
</tr>
</tbody>
</table>

Tissue preparation and analysis. Anesthetized mice were sacrificed by cervical dislocation, lungs and hearts removed and preserved in 10% neutral buffered formalin solution for at least 24 h. Organs were embedded in paraffin, sectioned and rehydrated. To assess collagen content in heart tissue, Sirius red staining solution was prepared with 0.5 g Direct Red 80 (Sigma) powder in 500 ml of saturated aqueous solution of picric acid (Sigma). Sirius red stains collagen I, II and III by reacting, via its sulphonic
acid groups, with basic groups of the collagen molecule (32). Slides were stained for 60 min, washed twice in acidified water (5 % v/v acetic acid), dehydrated and mounted using a resinous mounting medium. At least 5 photographs of left ventricular heart tissue were taken at 250x magnification in brightfield microscopy in a blinded manner. The content of red fibers (collagen) per section was determined using ImageJ software, and perivascular fibrosis was excluded from the calculation. A subset of slides was stained with Weigert's hematoxylin before Sirius red staining and was used for the generation of representative pictures of heart tissue. For quantification, slides without nuclear staining were used to avoid interference of hematoxylin with the quantification algorithm. Mosaics of representative areas of the left ventricle were generated using the MosaicJ plugin of ImageJ (33). For trichrome staining of lung tissue the Masson trichrome stain kit (Sigma) was used according to the manufacturer's protocol. Nuclei were not stained with hematoxylin to avoid interference with the quantification of collagen content. For quantification, at least 6 photographs of lung parenchyma were taken by brightfield microscopy by an investigator blinded to the identity of the samples. The area of blue fibers (collagen) per lung tissue (excluding empty alveolar spaces) was calculated using ImageJ software. Staining of heart tissue by trichrome stain was carried out in parallel. As these latter slides were not used for quantification, nuclei were stained using Weigert's hematoxylin.

Statistical analysis. Data are presented as means ± SEM. For statistical tests, a two-tailed Student's t-test or Mann-Whitney U-test was used when two groups were compared. For comparison of more than two groups, the one-way ANOVA with Bonferroni's post-test was applied. Correlation analysis was performed between the level of heart fibrosis and EF using GraphPad Prism 6.0d software. All P values below 0.05 were considered significant.

Both fibrosis and inflammation are closely associated with aging (18). The complex mechanisms involved in cellular deterioration with aging include the accumulation of DNA damage, mitochondrial dysfunction, increased susceptibility to apoptosis, telomere length shortening, epigenetic changes as well as oxidative stress (19, 20). It is known that elderly people experience significant changes in the function of their immune system, including a decline in the adaptive immune system, which creates an imbalance between adaptive and innate immune responses (21). Generally, aging leads to a more pro-inflammatory environment (22), with higher numbers of neutrophils and an increase in ROS production (5, 20) coupled with an increased susceptibility to pathogens and a higher
incidence of inflammatory diseases (21), such as neurodegenerative disorders, rheumatoid arthritis, osteoporosis, diabetes, cardiovascular disease as well as thrombosis (23). Intriguingly, many of these illnesses have been reported to involve NETs.

Both the heart and the lung appear to be susceptible to age-related fibrosis. In cardiac aging, fibrotic remodeling may lead to diastolic dysfunction due to increased ventricular stiffness and, possibly, systolic heart failure (26), which is the most common cause for hospitalization for patients older than 65 years (27). In addition, cardiac injury by coronary artery disease or perimyocarditis can add to the fibrotic changes of the aging heart, making it even more important to understand the mechanisms underlying this process.

Fibrotic lung diseases are characterized by enhanced collagen deposition in the airways, including the alveolar walls, and subsequent disturbance of pulmonary gas-exchange. Excessive fibrotic tissue remodeling is a predominant feature of many chronic lung diseases. Fibrotic lung diseases affect a large part of the older population (28-30) and include chronic obstructive pulmonary disease (COPD), fibrotic reactions after acute or chronic lung infections, inhalation of pulmonary irritants, autoimmune or allergic diseases and idiopathic pulmonary fibrosis (IPF) an aggressive form of lung fibrosis with no proven treatment option. Importantly, both COPD and IPF are again clearly associated with aging (30, 31). Given the need for a better understanding of the complex mechanisms linking inflammation to fibrosis and aging, the goal of this study was to determine if there is interplay between PAD4/NETs, fibrosis and aging.

**Results**

**Neutrophil susceptibility to form NETs increases with mouse age**

There are many changes that occur in the aging immune system, including an increase in hematopoietic stem cells of the myeloid lineage versus cells of the lymphoid lineage (34). To further study the effect of aging in mice, we examined blood and neutrophils from young (8-16 weeks) and old (24-27 months) mice obtained from the NIH's NIA C57BL/6 Aged Rodent Colony. We were able to confirm that in these mice, neutrophil counts were elevated with age (Figure 5A), along with platelet counts (Figure 5B). Using citrullinated histone H3 (FBCit) as a biomarker of PAD4 activity and neutrophil priming for NETosis, we examined basal levels of circulating H3Cit+ cells and found that a greater percentage of neutrophils were primed toward NETosis in the old mice (Figure 5C). We also saw that a higher percentage of circulating leukocytes were neutrophils in the old mice using the neutrophil-specific marker Ly6G (Figure 5D). To evaluate whether neutrophils from the
older animals had a greater tendency to release NETs, we isolated peripheral blood
neutrophils and stimulated them with calcium ionophore or PMA. We found that after
incubation, both with or without stimulation neutrophils from older mice had a greater
propensity to form NETs as quantified by microscopy (Figure 5E). Taken together, these
observations indicate that in aging mice, NET formation is likely to be exacerbated. We
hypothesized that increased NETosis, and the deleterious effects of NET formation, may lead
to organ fibrosis. To study this, we focused on spontaneous organ fibrosis that occurs with
natural aging in mice.

PAD4−/− mice are protected from age-related decline in heart function

In C57BL/6 mice, NETosis is dependent on the histone modifying enzyme
PAD4. Using PAD4−/− mice or DNase 1 infusion in WT mice, our group has previously shown
that extracellular DNA/NETs have deleterious effects on heart function in the setting of acute
myocardial injury (11). Therefore, we hypothesized that increased NETosis in old WT mice
might constitute a chronic insult to the myocardium, resulting in a decline of heart function,
and that reduction of NETosis in PAD4−/− mice might have protective effects. We performed
echocardiography on WT and PAD4−/− retired breeders (12-17 months old), using age- and
sex-matched groups of males and females. The mice were housed in the same animal room
and had received an enriched "reproduction diet" throughout their life. Blood cell counts, body
weights and blood pressure were not significantly different between the two genotypes (Table
2). We evaluated the left ventricular ejection fraction (LVEF) of these animals (Figure 6A)
and found that WT retired breeders showed a decline in their LVEF to 50.7%, consistent with
literature on heart function in aging WT mice (35). Surprisingly, however, old PAD4−/− retired
breeders retained a significantly better heart function with an average LVEF of 61.2%,
comparable to the LVEF of young mice (Figure 6B, first panel). No differences were seen
between male and female mice. End-diastolic dimensions of the heart such as the diameter of
the interventricular septum (IVS;d), the left ventricular posterior wall (LVPW;d) and left
ventricular inner diameter (LVID;d) were assessed in both groups of mice (Figure 2A) to
check for possible significant dimensional differences such as severe ventricular dilation or
wall hypertrophy that could underlie the observed changes in heart function. None of the
measured structural parameters yielded significant differences between the two genotypes,
suggesting that myocardial contractility and thus heart function itself is compromised in old
WT but not PAD4−/− breeders.
To exclude the possible effects of the reproduction diet received by the retired breeders, we repeated all echocardiographic measurements on groups of WT and PALM−/− mice that were allowed to age on standard lab diet (Figure 6B, 6C). Old WT and PAD4−/− mice were 14-18 months old, age- and sex-matched and housed in the same animal room. In addition, LVEF was measured in young gender-matched mice (6-8 weeks) on standard diet. Again, the old WT mice showed a decline in LVEF (Figure 6B) compared to the young WT mice, with similar LVEF values to those observed in the retired WT breeders. This indicates that the reduction in heart function in old mice was independent of the dietary factors in our study. In this second group, the old PAD4−/− mice again had a significantly higher mean LVEF that was comparable to the means seen in young PALM−/− or WT mice (Figure 6B, first panel), corroborating that PALM−/− mice are protected from an age-dependent decline in systolic heart function. Measurement of structural parameters again showed similar heart dimensions for old WT and PAD4−/− mice on standard diet with no significant differences for IVS;d, LVPW;d and LVID;d (Figure 6B, 6C).

In contrast to the notable decline in LVEF seen in mice with old age, in humans, age-associated decline of heart function is mostly associated with diastolic dysfunction (36, 37). For that reason, we evaluated signs of diastolic dysfunction in a set of old WT (14-20 months) and old PAD4−/− (18 months) mice on standard diet and compared to young WT and PALM−/− (2 months) mice. Specifically, the mitral inflow pattern was measured by echocardiography (Figure 6D and 6E) and the ratio between the E wave (representing the early, passive filling of the ventricle during diastole) and the A wave (representing the active filling of the ventricle by atrial contraction) was calculated. Representative images are shown in Figure 6E. Generally, an E′A ratio of less than 1 is considered a sign of impaired ventricular relaxation and, hence, diastolic dysfunction, which can be caused by increased stiffness of the heart. In the old WT non-breeder mice, the average E′A ratio was 0.83, corroborating our previous observation of heart dysfunction in these mice (Figure 6D and 6E left panel). In contrast, none of the PALM−/− old non-breeders showed signs of diastolic dysfunction: the average E′A ratio was 1.44 and significantly higher compared to old WT mice (Figure 6D and 6E, right panel). Unlike the old WT mice, old PAD4−/− did not have a significant decline in E′A ratio compared to young PAD4−/− mice. Thus, only in the PAD4−/− mice was the heart function preserved in old age.

PAD4−/− mice have significantly less interstitial myocardial fibrosis than WT mice.
As old WT mice had clearly reduced heart function compared to old PAD4−/− mice without significant changes in heart dimensions, we aimed to determine if there were tissue changes in the myocardium. As organ fibrosis is a form of tissue remodeling often associated with old age and chronic inflammation, it seemed possible that the functional changes were due to an increase in myocardial fibrosis with age. We therefore harvested the hearts of WT and PAD4−/− retired breeders (n = 6) and assessed interstitial heart fibrosis by Sirius red stain, which is used to identify and quantify collagen in cardiac tissue (32, 38, 39) (Figure 7A, 7C and 7D left panels). Perivascular staining was excluded from this analysis. Interestingly, WT retired breeders showed significantly more interstitial fibrosis than the age-matched 12-17 months PAD4−/− mice (Figure 7A). In contrast, Sirius red-positive collagen fibers in the PAD4−/− breeder hearts were mainly located around vessels with little interstitial fibrosis (Figure 7C). We performed the same analysis in the old WT and PAD4−/− non-breeders and found a similar difference between the WT and the PAD4−/− mice (Figure 7B). Additionally, the hearts of young WT and PAD4−/− mice were assessed to determine whether a fibrosis difference between the genotypes was already present at an early age. At 6-8 weeks WT and PAD4−/− mice had comparably low interstitial heart fibrosis (Figure 7B), indicating that the observed difference between WT and PAD4−/− mice was indeed an age-related phenomenon. Remarkably, in the old PAD4−/− non-breeders, the amount of fibrotic tissue remained similar to that of young PAD4−/− or WT mice, indicating that those old mice were protected from age-related myocardial interstitial fibrosis. Increased fibrosis in old WT compared to old PAD4−/− myocardium could also be observed qualitatively by Masson’s trichrome staining (Figure 7D, right panels), another type of staining commonly used to visualize collagen and fibrotic tissue changes (40, 41).

In spite of the significant visible difference in interstitial fibrosis between old WT and PAD4−/− mice, the determined percentage of interstitial fibrotic area appeared low. Therefore, we wondered whether the difference in fibrotic tissue within the heart could explain the difference in functionality in the two groups. Correlation analysis of level of heart fibrosis and LVEF of all mice was performed and indeed showed a significant (P < 0.03) negative correlation, with a correlation coefficient (r) of -0.44. Although this result does not exclude additional factors in the development of heart dysfunction, it is highly probable that fibrosis determines tissue properties such as stiffness (26, 42) and thus organ function in these mice.

Age-related interstitial pulmonary fibrosis is reduced in PAD4−/− mice compared to WT mice
After the surprising finding that PAD4−/− mice were protected from myocardial interstitial fibrosis in old age, we sought to extend our study to a second organ system that is highly susceptible to age-/inflammatory disease-related fibrosis. We assessed pulmonary interstitial fibrosis for both WT and PAD4−/− genotypes in the retired breeders and also in the old non-breeders and in young mice. The lungs of retired PAD4−/− breeders also had significantly less organ fibrosis as assessed by Masson's trichrome stain, compared to WT retired breeders (Figure 8A). In the old mice on standard lab diet, the difference was also highly significant (Figure 8B, 8C). Compared to young mice, both WT and PAD4−/− old mice showed an age-related increase in collagen deposition in the lung (Figure 8A). However, in the WT mice, this increase was more pronounced.

Thus, our data show that aging is associated with an increase of interstitial fibrosis in different organs as determined by two different histochemical stains for collagen. PAD4−/− mice are, to a great degree, protected from this age-associated fibrosis.

DISCUSSION

Understanding the mechanisms leading to age-related organ dysfunction is essential for providing adequate care for our rapidly aging population. Thus, the goal of the present study was to investigate the interplay between aging, PAD4/NETs and organ function.

In spite of their proposed protective role in infectious diseases (6), NETs and their components are cytotoxic, pro-inflammatory and pro-thrombotic (10, 12, 43). Elevated levels of NETs are associated with a number of non-infectious diseases such as autoimmune disease (44-46), arteriosclerosis (47), cancer (16), DVT (14, 48) and myocardial infarction(1 1), all of which present a growing challenge to the health care system as the incidence of these diseases increases dramatically with age. Excessive NET formation is not only a side-product of these diseases, butNETs themselves can also negatively impact organ function as we have recently shown in an acute model of MI/R (11). Mice with a defect in forming NETs because they lack the enzyme PAD4 maintain a significantly better heart function after acute MI/R (11) and are also protected from venous thrombosis (13) that too may be triggered by hypoxia (49).

While these diseases in which NETs are implicated have a higher incidence in old age, neutrophil function and the predisposition to form NETs itself may be altered in the aging individual. It is known that the balance between innate immunity and adaptive immunity shifts towards innate immunity with a decrease in lymphocytes accompanied by
either an increase or no change in neutrophil counts in older people (50, 51). An increase in
neutrophil counts and neutrophil percent of total leukocytes was found in the old mice in our
study compared to young mice. In humans, the expansion of the neutrophil population is
accompanied by an increase in ROS production by the neutrophils (5). Interestingly, ROS
have been shown to be inducers of NETosis (25, 52), thus providing a possible link between
old age and NETosis. In addition, aging humans are known to have elevated platelet counts,
as was also shown in our animal model. Interestingly, activation of platelets through TLR4
and their subsequent interactions with neutrophils have been proposed to stimulate NETosis
(53). In our study, the propensity of neutrophils from older mice for PAD4-mediated histone
citrullination and NET formation was significantly elevated compared to young mice after
exposure to PMA, a ROS-dependent inducer of NETosis, and ionomycin, a ROS-independent
stimulator that directly induces calcium influx into the cells and activates PAD4 (25). Even
without stimulation, neutrophils from old mice had higher baseline values of H3Cit and
produced more NETs after isolation. To our knowledge this is the first study evaluating NET
formation in peripheral blood neutrophils from aging mice. One previous publication showed
that neutrophils that had extravasated into the peritoneum had a reduced propensity to form
NETs in older mice (54), but this recruited peritoneal neutrophil population is likely
modified/activated by the transmigration and less likely to form NETs (55).

[00254] To assess whether organ function in old age was affected by the excessive
ability of the old mice to form cytotoxic NETs, we measured heart function in old mice that
either could form NETs (WT) or were defective in NETosis (PAD4−/−), both in retired breeders
and in mice that had received standard lab diet throughout their life. We chose this organ
system as our group has previously shown in an acute model of MI/R that the PAD4−/− mice
are protected from a decline in heart function compared to WT mice. Aging can cause
myocardial damage via excessive ROS production by mitochondria-rich cardiomyocytes (56),
and extracellular ROS augment neutrophil-endothelial interactions (57). We were thus
interested whether in old age, which is accompanied by an elevated activation of NETosis, a
long-term release of NETs would also lead to differences in heart function. Interestingly, we
observed a significant difference between both the systolic and the diastolic functional
measurements in old WT versus old PAD4−/− mice. While WT mice had an age-related,
expected decline of LVEF with values very similar to those previously reported in the
literature (35), LVEF in the old PAD4−/− mice remained comparable to that of young mice,
both for systolic (LVEF) as well as diastolic (E/A ratio;) parameters. Therefore, the aging
mouse heart could be undergoing chronic injury due to NET formation over time, negatively affecting heart function even in the absence of a specific event such as myocardial infarction.

[00255] Age-related structural remodeling of the human heart and decline of heart function is associated with cardiomyocyte hypertrophy and interstitial fibrosis. In young, healthy hearts, myocytes and myocardial bundles are surrounded by thin layers of connective tissue, the endomysium and perimysium, respectively. In contrast, with age, extracellular matrix proteins accumulate in the interstitium and result in endomysial and perimysial fibrosis (42). We used Sirius red staining to identify collagen in the myocardium and to assess interstitial fibrosis in the old and young WT mice. We found an increase in interstitial fibrosis in the old WT mice. However, such an age-related increase was absent in old PAD4−/− mice. While collagen and other extracellular matrix (ECM) components play an important role in maintaining tissue integrity and provide "healthy signaling," it is likely that excessive ECM accumulation reduces ventricular compliance and impairs cardiac function, both diastolic and systolic (42), as we have seen in the old WT mice. That an increase in interstitial fibrosis is a relevant factor in the age-related functional decline of the WT hearts was further corroborated by an inverse correlation between the extent of interstitial fibrosis and the LVEF of mice.

[00256] Another organ highly susceptible to fibrosis is the lung (28, 30). Here, however, the age-related fibrosis we observed was only in part dependent on PAD4 expression. Respiration exposes the airways of the lung to the outside world and injury leading to fibrosis could be contributed by minor infections resulting in injurious cytokine production and/or inhalation of particulate matter. However, even in the old lungs PAD4-deficiency significantly reduced fibrosis, which might lead to improved lung performance.

[00257] The reduction of interstitial collagen in the PAD4−/− mice and the protection from heart malfunction is striking and brings up the question as to why PAD4−/− mice would be protected from fibrosis in old age. As mentioned above, histones, the main protein component of NETs (58), have been shown to have cytotoxic effects on endothelium and epithelium (10, 59). Chronic elevation of these components in tissue might therefore lead to perpetual injury and the formation of excess ECM. Furthermore, neutrophil elastase, a protease which is released along with NETs, has been shown to directly contribute to lung fibrosis in an animal model of bleomycin-induced lung injury (60). A recently published study proposed a direct link between NETs and fibrosis (61). In this study, NETs promoted differentiation of lung fibroblasts in culture into a myofibroblast phenotype which in turn
demonstrated increased connective tissue growth factor expression, collagen production and proliferation/migration. It is therefore reasonable to hypothesize that in vivo, NETs may similarly modify cellular behavior, thus promoting fibrosis.

[00258] Our results suggest that old age per se can be seen as a "NET-inducing state" with NET-dependent consequences to the organism. However, examining the organ function of old mice or aging humans, the damage to any organ system is likely the sum of insults over a lifetime. The NET-inducing events that might contribute to organ dysfunction include hypoxia, mechanical injury and various types of infections. As humans are much more exposed to such stressors than mice living in a protected specific pathogen-free environment, one would expect the unfavorable effects of life to be of even more consequence in humans than in laboratory mice.

[00259] Our study on aging in mice indicates that limiting PAD4 activity and excessive NET production in known NET-inducing diseases, especially in old age, would be beneficial. NET-targeted therapeutics could involve digesting NETs with DNases, inhibiting their formation with agents such as PAD4 inhibitors, or neutralizing their toxic components such as histones or elastase (10, 62). These approaches will have positive long-term effects on organ function and perhaps even longevity of individuals.

[00260] Example 2 References


42. Frangogiannis ABaNG (Aging and Cardiac Fibrosis. *Aging and Disease*.


[00261] **Sequence Listing**

**SEQ ID NO:** 1  **PAD4 mRNA**  **NCBI Ref Seq:**

<table>
<thead>
<tr>
<th>NM_012387</th>
</tr>
</thead>
</table>

1  acagccagag ggacagctga gcccgcagat ggccccagggg acatggatcc ggtgcaccc
61  agagccagccc accccctgcgg tgtggttgtct gggccacctg atccgtcctg acatcgcag
121  cctcgcctccc gaggctctgaa cgtctctccat ctaacaagcc tcccaagggg tgggctgtgga
181  tatttgccccc gcgcctccag ccaagaagaa atccacaggt tcttccacat gcccccagga
241  cctcgggtgaa agggtcctctc gaggagcctag tgcgcacag gccggggtgc ggacatgcag
301  ggttccagatt tcatactacg gaccccaagac tccaccagtc aagccctcctc tctactcac
361  cgccggggaa atctctcttt cggccagcac ccaccgcacc gccaagatga ggccaccagc
421  agctgtgaaa gatcagagga cttggacactc gggccctttg ggtacaggttg ccacccctgc
481  gttgaaacct cagacagaca actctgcaacc tcttccctccat gactgcgcagtg atgtgaagat
541  gctgcagcgc gaggacctgc aggcctagtgc gctgtagacct gcagacacag gaagcccccag
601  ggacctcttc cacaacacaat cactaggtgtct cccagctggcc agtgctggaga tggccagaaat
661  gagggttttt gcagcccaac gccgccaact tccggccactg gtcgctgtga tctctgctcctggctcctgctcc
721  caagttggccc tctctacttc tgtagttccttc cggtgagagac ccaacagtgg acctctcagt
781  ggagcccccct gcgtctccggg acacccggct cccgggcttc ataccctctca ccattctctctg
841  gctggacagcc tccacattgg tgtgccgcag tgcgctgagtc tccacagaca gcggtgtctct
901  cccgcgtttggt cccctggtata ggccccccca cccccacccag ccgcagggggt gtacgcctgtg
961  cgatatttttt cagatttggag tctctcttgag actcttgctca actcttgctc agaaccgccac
1021 gtctgaaagtct cacatttgcc ctgagagagc cgaacatggat gacacagagat gcagaggtga
tgacgcctgtgct
tgactcttctcc
1141 aaggcacacc gcgccttgcag gatgcttccttg ccaacagctg atggtgctgag attttgcctgc
1201 tggttacactg gcggcccaaa cggggtgttt catgctgctag actctgctgac tggagctgtgc
1261 agtgagcccc cccagctcagc tccaagggcag gataactcag ctggtgagcct ctctctctcg
1321 gacagcagct tattaccagca agtcagccag cagaggctcgc agactctttc
1381 cagttgcccag caggtgctag cccccctgtaa gctctttctt gacttgtctg ccggccgca
1441 gttggagcag ttcctgagctg ttcggcgcag cccgagccgg ggcgtgctct
1501 gcgcagccccc aggttctctgc acaacattgt ccagagagagc cagatgcagg gcacgggggga
1561 gccccttgct ctgctggaga ccaagaaa aaaaagacag aaaaatagaag ccattctgtc
1621 aacaoaacaca tttgagagac atactttcgtt ctgatgagagc gcagagctgag gcacggggga
1681 gttgctgattc gcggagtcgg gcctggtcgg agtgacacat tccttcctgtt ccgccgctctcc
1741 caacgcccaaaa ggtttcttcgg aagggcttcc gcgtcggcac ccgtcgtcctt cccggtctgctc
1801 gcctagggag ccctgctgcgg tcccccagcc ctctggggtc ctgcatcagg gcgcgtctgc
1861 cctggagagg tagtgcgtgt cctctgcttg gccctgctgg ccctgtgctca cctctccttcac
1921 cgcaactttc aacctacccca cagcagcatgg gcaggtgcag tcggccacag acgtggccagc
1981 aagcccccctc tctttcagtg ggtggaacag ggtgcttgctgc gcccacccctc cctggcgcctc
What is claimed herein is:

1. A method of treating or preventing organ fibrosis in a subject, the method comprising:
   administering to a subject in need of treatment, a therapeutically effective
   amount of at least one anti-NET compound.

2. The method of claim 1, wherein the at least one anti-NET compound is selected from
   the group consisting of:
   DNase; a histone-degrading enzyme; an inhibitor of chromatin
   decondensation; an antibody against a component of a NET; a protease
   inhibitor, an elastase inhibitor; and a PAD4 inhibitor.

3. The method of any of claims 1-2, wherein the PAD4 inhibitor is selected from the
   group consisting of:
   Cl-amidine and F-amidine.

4. The method of any of claims 1-3, wherein said therapeutically effective amount of
   anti-NET compound is administered prophylactically.

5. The method of any of claims 1-4, wherein the subjects age is selected from the group
   consisting of: over 40 years of age, over 30 years of age, over 50 years of age, over 60
   years of age, and over 70 years of age.

6. The method of any of claims 1-5, wherein the subject is diagnosed with a disease
   selected from the group consisting of: heart disease, lung disease, kidney disease,
   liver disease, and diabetes.

7. The method of any of claims 1-6, wherein said therapeutically effective amount of
   anti-NET compound is given repeatedly.

8. The method of any of claims 1-7, wherein the subject is diagnosed as having age-
   related organ fibrosis.

9. The method of any of claims 1-8, wherein the subject is diagnosed with an organ
   fibrosis selected from the group consisting of; heart fibrosis, lung fibrosis, liver
   fibrosis, kidney fibrosis, skin fibrosis, soft tissue fibrosis, and intestine fibrosis.

10. The method of any of claims 1-9, wherein the administration is local administration to
    one or more target sites in an organ having fibrosis.

11. The method of any of claims 1-10, wherein the subject does not have cystic fibrosis.
A method for facilitating wound healing comprising administering a therapeutically effective amount of at least one anti-NET compound.

The method of claim 12, wherein the anti-NET compound is selected from the group consisting of:

- DNase; a histone-degrading enzyme; an inhibitor of chromatin decondensation; an antibody against a component of a NET; a protease inhibitor, an elastase inhibitor; and a PAD4 inhibitor.

The method of any of claims 12-13, wherein a DNAse and an additional anti-NET compound selected from the group consisting of: a histone-degrading enzyme; an inhibitor of chromatin decondensation; a NET release inhibitor; an antibody against a component of a NET; a protease inhibitor, an elastase inhibitor; and a PAD4 inhibitor, are administered.

The method of any of claims 12-13, wherein the anti-NET compound is not a DNAse.

The method of any of claims 12-15, wherein the PAD4 inhibitor is selected from the group consisting of:

- Cl-amidine and F-amidine.

The method of any of claims 12-16, wherein said therapeutically effective amount of anti-NET compound is administered prophylactically.

The method of any of claims 12-17, wherein said therapeutically effective amount of anti-NET compound is given repeatedly.

The method of any of claims 12-18, wherein the subject is diagnosed as having diabetes.

A method for treating NET associated inflammation and complications in diabetes comprising administering a therapeutically effective amount of at least one anti-NET compound.

The method of claim 20, wherein the anti-NET compound is selected from the group consisting of:

- DNase; a histone-degrading enzyme; an inhibitor of chromatin decondensation; a NET release inhibitor; an antibody against a component of a NET; a protease inhibitor, an elastase inhibitor; and a PAD4 inhibitor.

The method of any of claims 20-21, wherein the anti-NET compound is not a DNAse.

The method of any of claims 20-22, wherein the anti-NET compound is not an elastase inhibitor.
24. The method of any of claims 20-23, wherein the PAD4 inhibitor is selected from the group consisting of:
   Cl-amidine and F-amidine.
25. The method of any of claims 20-24, wherein said therapeutically effective amount of anti-NET compound is administered prophylactically.
26. The method of any of claims 20-25, wherein said therapeutically effective amount of anti-NET compound is given repeatedly.
27. The method of any of claims 20-26, wherein the subject is diagnosed as having diabetes type I.
28. The method of any of claims 20-27, wherein the subject is diagnosed as having diabetes type II.
29. The method of any of claims 20-28, wherein inflammation is reduced by at least 10%, at least 20%, at least 30%, or at least 50% as compared to inflammation prior to treatment.
**FIG. 1E**

**FIG. 1F**

**FIG. 1G**
FIG. 2A

FIG. 2B
**FIG. 3A**

<table>
<thead>
<tr>
<th>Day</th>
<th>Genotype</th>
<th>Day 1</th>
<th>Day 3</th>
<th>Day 7</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>+/-</td>
<td>+/-</td>
<td>+/-</td>
</tr>
<tr>
<td></td>
<td></td>
<td>+/-</td>
<td>+/-</td>
<td>+/-</td>
</tr>
<tr>
<td></td>
<td></td>
<td>+/-</td>
<td>+/-</td>
<td>+/-</td>
</tr>
<tr>
<td></td>
<td></td>
<td>+/-</td>
<td>+/-</td>
<td>+/-</td>
</tr>
</tbody>
</table>

- H3Cit
- H3
- Ly6G
- GAPDH

**FIG. 3B**

<table>
<thead>
<tr>
<th>Days post-wounding</th>
<th>0</th>
<th>1</th>
<th>3</th>
<th>7</th>
</tr>
</thead>
<tbody>
<tr>
<td>WT</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PAD4⁻</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**FIG. 3C**

Bar graph showing wound area (% of Day 0) over different days post-wounding (1, 3, 7, 14) for WT and PAD4-/- mice.

**FIG. 3D**

Bar graph showing % of mice with total wound closure at days 13 and 14 post-wounding, with comparisons for WT and PAD4-/- mice.

**FIG. 3E**

Scatter plot demonstrating re-epithelialization (mm) with a comparison between WT and PAD4-/- mice.
FIG. 6E
FIG. 10A

FIG. 10B

FIG. 11
Scheme 2. Reagents and conditions: (i) Ph3P, DIAD and THF; (ii) Cu(OAc)2, Na ascorbate, H2O/t-BuOH 1/1 and intermediate A; and (iii) HClaq 3M [34].

---

**FIG. 13**

- **(A)**

  - $R\ O\ OR_1$
  - $i)$ $\text{Br}_m\text{Br}$, TEA, DCM
  - $ii)$ NaN₃, DMF

  Intermediate A

  - $R_1 = \text{Me, Et}$

- **(B)**

  - $\text{OH}$, $n$-
  - $\text{N}^\text{Boc}$
  - $i)$ $\text{HN}$, $\text{Boc}$
  - $ii)$ $\text{HN}$, $\text{Boc}$
  - $iii)$ $\text{HN}$, $\text{Boc}$

  1-11

<table>
<thead>
<tr>
<th>n</th>
<th>m</th>
<th>m</th>
<th>R</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1</td>
<td>1</td>
<td>Ph</td>
</tr>
<tr>
<td>2</td>
<td>1</td>
<td>1</td>
<td>(R) Ph</td>
</tr>
<tr>
<td>3</td>
<td>1</td>
<td>1</td>
<td>(S) Ph</td>
</tr>
<tr>
<td>4</td>
<td>1</td>
<td>1</td>
<td>(R) 4F-Ph</td>
</tr>
<tr>
<td>5</td>
<td>1</td>
<td>1</td>
<td>(S) 4F-Ph</td>
</tr>
<tr>
<td>6</td>
<td>1</td>
<td>1</td>
<td>(R) Ph</td>
</tr>
<tr>
<td>7</td>
<td>1</td>
<td>1</td>
<td>(S) Ph</td>
</tr>
<tr>
<td>8</td>
<td>1</td>
<td>1</td>
<td>(R) 4F-Ph</td>
</tr>
<tr>
<td>9</td>
<td>1</td>
<td>1</td>
<td>(S) Ph</td>
</tr>
<tr>
<td>10</td>
<td>1</td>
<td>1</td>
<td>H</td>
</tr>
<tr>
<td>11</td>
<td>1</td>
<td>2</td>
<td>Ph</td>
</tr>
</tbody>
</table>
Scheme 3. Reagents and conditions: (i) Et3N and DCM; (ii) Cu(OAc)2, Na ascorbate, H2O/t-BuOH 1/1, Intermediate A; and (iii) HClaq 3M [34].

FIG. 13 (cont.)
Scheme 4. General synthetic scheme of compound 16 [34].


FIG. 13 (cont.)
**INTERNATIONAL SEARCH REPORT**

International application No. PCT/US2016/013847

A. CLASSIFICATION OF SUBJECT MATTER

<table>
<thead>
<tr>
<th>IPC(8)</th>
<th>CPC</th>
<th>According to International Patent Classification (IPC) or to both national classification and IPC</th>
</tr>
</thead>
<tbody>
<tr>
<td>A61K 38/46 (2016.01)</td>
<td>A61K 31/166 (2016.02)</td>
<td></td>
</tr>
</tbody>
</table>

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

<table>
<thead>
<tr>
<th>IPC(8)</th>
<th>CPC</th>
</tr>
</thead>
<tbody>
<tr>
<td>A61K 31/155, 31/166, 38/43, 38/46, 39/395, 45/06; A61M 1/34; A61P 7/00; G01 N 33/53 (2016.01)</td>
<td></td>
</tr>
<tr>
<td>A61K 31/155, 31/166, 38/465, 38/49, 39/3955, 45/06; A61M 1/34; G01N 2800/102, 2800/104, 2800/285, 2800/368, 2800 (2016.02)</td>
<td></td>
</tr>
</tbody>
</table>

Documentation searched other than that to which extent such documents are included in the fields searched

USPC - 210/435/000; 424/94.600; 172.100; 435/2.000, 307.100; 514/616.000 (keyword delimited)

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Orbit, Google Patents, Google Scholar.

Search terms used: net nets netosis (treating OR preventing OR inhibiting OR inhibitor) dna amidine diabetes wound healing inflammation antibody

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>12-15, 20-22</td>
</tr>
<tr>
<td>Y</td>
<td>WANG et al. <em>Increased neutrophil elastase and proteinase 3 and augmented NETosis are closely associated with β-cell autodestruction in patients with type 1 diabetes,</em> Diabetes, 4 August 2014 (04.08.2014), Vol. 63, Pgs. 4239-4248, entire document</td>
<td>20-22</td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of Box C. See patent family annex.

- Special categories of cited documents:
  - "A" document defining the general state of the art which is not considered to be of particular relevance
  - "E" earlier application or patent but published on or after the international filing date
  - "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
  - "O" document referring to an oral disclosure, use, exhibition or other means
  - "P" document published prior to the international filing date but later than the priority date claimed
  - "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
  - "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
  - "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
  - "Z" member of the same patent family

Date of the actual completion of the international search 25 March 2016

Date of mailing of the international search report 21 APR 2016

Name and mailing address of the ISA/Authorized officer

Blaine R. Copenhaver
PCT Helpdesk: 571-272-4300
PCT OSP: 571-272-7774

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, VA 22313-1450
Facsimile No. 571-273-8300
<table>
<thead>
<tr>
<th>Box No.</th>
<th>Nucleotide and/or amino acid sequence(s) (Continuation of item 1c of the first sheet)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:</td>
</tr>
<tr>
<td></td>
<td>a. ☐ forming part of the international application as filed:</td>
</tr>
<tr>
<td></td>
<td>☐ in the form of an Annex C/ST.25 text file.</td>
</tr>
<tr>
<td></td>
<td>☐ on paper or in the form of an image file.</td>
</tr>
<tr>
<td></td>
<td>b. ☐ furnished together with the international application under PCT Rule liter. 1(a) for the purposes of international search only in the form of an Annex C/ST.25 text file.</td>
</tr>
<tr>
<td></td>
<td>c. ☒ furnished subsequent to the international filing date for the purposes of international search only:</td>
</tr>
<tr>
<td></td>
<td>☒ in the form of an Annex C/ST.25 text file (Rule 13/er. 1(a)).</td>
</tr>
<tr>
<td></td>
<td>☐ on paper or in the form of an image file (Rule 13/er. 1(b) and Administrative Instructions, Section 713).</td>
</tr>
<tr>
<td>2.</td>
<td>☒ In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that forming part of the application as filed or does not go beyond the application as filed, as appropriate, were furnished.</td>
</tr>
<tr>
<td>3.</td>
<td>Additional comments:</td>
</tr>
</tbody>
</table>

Form PCT/ISA/210 (continuation of first sheet (1)) (January 2015)
### Box No. II  Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☑ Claims Nos.: 4-11, 16-19, 23-29 because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box No. III  Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**

☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.

☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.

☐ No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (2)) (January 2015)